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I. Introduction 
 
 
 
1. Aggregation and disease 
Protein or peptide misfolding can be at the roots of various diseases by 
inducing reduced activity of the involved proteins or peptides. These diseases are 
referred to as protein misfolding diseases1. In most cases, protein or peptide 
misfolding converts the peptide or protein into an insoluble aggregate usually 
described as amyloid fibrils or plaques if accumulated outside of the cell1, or as 
intracellular inclusions if the accumulation occurs in the intracellular medium2. 
 
a) A broad range of diseases concerned 
The following examples illustrate the various disease areas affected by 
aggregation but they also illustrate the lack of knowledge with regard to aggregation. It 
is usually not known whether fibril formation causes the disease or is one of its 
consequences. In neurosciences, -synuclein, involved in both Parkinson’s disease and 
dementia with Lewy bodies, is the main component of Lewy bodies, forming insoluble 
protein-fibrils. These and the loss of dopaminergic neurons are hallmarks of the 
disease3, but no direct correlation between the physiological characteristics and the 
disease symptoms or development could be made yet4,5. In the same disease area, 
Huntington’s disease is hereditary and is characterized by aggregated huntingtin 
expanded with polyglutamine that forms intranuclear and cytoplasmic inclusions6,7. 
The inclusions themselves do not seem to be the cause of the toxicity and the 
mechanism of polyglutamine expansion remains unclear8. In the metabolic diseases 
area, the insolubilization of human islet amyloid polypeptide (IAPP) progressively 
forms pancreatic islet amyloids, toxic to the pancreatic -cells that produce IAPP 
together with insulin9. The cause and mechanism that lead to IAPP aggregation and 
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hence type II diabetes are not solved yet. However recent findings suggested that IAPP 
fibril formation is enhanced by dimerization of the protein as -helices. This discovery 
induced the search for an aggregation blocker in insulin, that is, a molecule which can 
interact with the dimerization interfaces10. In ophtalmology, -cristallins helps 
preventing aggregation of eye lens proteins and thus reduces the scattering on the 
lens that can in turn interfere with vision11. Extensive oxidation of cysteine and 
methionine residues12 in -cristallins sequence is a characteristic of aggregated eye 
lens proteins; it prevents the protein to play its role as chaperon and could lead to 
cataract by increased protein aggregation13,14. However it is not proven yet whether 
the aggregates are the cause or the consequence of the disease14.  
 
b) Alzheimer’s disease (AD) 
Alzheimer’s disease (AD) like other neurodegenerative diseases is 
characterized, among others, by the formation of plaques, that is, the accumulation of 
peptides on the neurons1. The mechanism of the amyloid peptide toxicity remains 
unexplained. Currently the most commonly accepted hypothesis is the amyloid 
cascade hypothesis. It stipulates that the formation of AP under the action of the 
secretases is at the origin of AD15,16. In parallel, the tau hypothesis is also discussed 
according to which hyperphosphorylation of the tau protein could be the cause of the 
disease17. But many other hypothesis have appeared over the years, emphasizing 
alternatively the calcium level18, metal ions19, or oxidative stress20 as important in the 
development of AD.  
The plaques detected in the brain of AD diseased patients are mainly composed 
by the amyloid peptide AP, a 39-42 amino-acid peptide21 (Figure 1).  
Figure 1: One-letter code amino-acid sequence of AP(1-40) and (1-42). The negatively- and 
positively-charged residues under physiological conditions are highlighted in pink and orange 
respectively, while the green amino acids show the intra-membrane part of the peptide. 
 
The much larger amyloid peptide precursor (APP) can be cleaved by three 
different secretases, the -, - and -secretase. AP(1-40) to AP(1-42) originate from 
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the successive cleavage of the amyloid peptide precursor (APP) by the - and -
secretase22-24. The amyloid  peptides AP(1-40) and AP(1-42) have a very low 
solubility, are highly hydrophobic and neurotoxic25-27. The production of AP(1-40) and 
AP(1-42) by the  and -secretases is known as the amyloidogenic pathway (Figure 2). 
In contrast, the cleavage of APP by the -secretase produces a soluble peptide28. This 
second pathway is named non-amyloidogenic. Figure 2 represents the amyloidogenic 
and non-amyloidogenic pathways. The accumulation of insoluble AP(1-40) or AP(1-
42) on the membrane surface leads to aggregation of these molecules, first as small 
oligomers and eventually as major plaques29.  
 
 
Figure 2: Schematic representation of the amyloidogenic and non-amyloidogenic pathways of 
APP processed by the -, - and -secretases22. 
 
c) The seeding mechanism in fibril formation 
The reason of amyloid  peptide aggregation is still unclear. Nevertheless a 
hypothesis describing the various stages of aggregation in a nuclei-seeded manner was 
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formulated about a decade ago30. The nucleation-dependent mechanism involves 
three steps, namely a slow nucleation step with lag phase, a faster protofibril 
formation containing a finite number of nuclei, and a thermodynamically favorable fast 
fibril elongation phase. Finally an equilibrium phase is reached where the soluble 
peptides coexist with the aggregated species31. Nucleus formation is considered to be 
the kinetic barrier of fibrillogenesis30. The period needed for nucleus formation is 
called lag-phase. It can be considerably shortened or even be nonexistent with the 
addition of heterogeneous seeds, such as lipids32 or metal ions33, or by the presence of 
a catalytic surface34. The presence of the nucleus facilitates further addition of 
monomers or intermediates that will elongate the nucleus to progressively form 
protofibrils and then fibrils30,35,36. The seeding model is suitable to explain the kinetics 
of fibril formation, the length of the lag phase, the rate of elongation and the distinct 
concentration dependence of the aggregation measured by fluorescence techniques37-
39.  
The seeding model evolved over the years with the parallel discovery of new 
types of intermediates and of new rate-influencing factors. More recently, 
modifications include a rate-limiting step modulated by the peptide concentration40, a 
second nucleation step overcoming the nuclei formation when fibrils are formed in 
sufficient quantities41, or various intermediate species such as oligomers and 
protofibrils31. 
 
Figure 3: Schematic representation of the nuclei-dependent fibrillization. The monomers 
associate and undergo conformational change to first form aggregates of monomers and then 
a nucleus after a series of unfavorable equilibrium. Once the nucleus is formed, the quick 
addition of monomers or aggregates lead to protofibril and then fibril formation37,40,42. 
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Other models exist that try to describe the fibrillization, considering other steps 
as rate-limiting43, but the seeding model is able to explain most of the published 
experimental fibrillogenesis data44. It can be represented with the scheme in Figure 3.  
 
 
2. Toxicity and conformation 
a) Origins of toxicity 
For a long time, fibrils were thought to be responsible for the observed 
neurodegeneration, not only for AD, but also for other neurodegenerative 
diseases45,46. More recently the non-fibrillar oligomers of amyloid  peptide, AP47,48, 
-synuclein, or IAPP were found to be more toxic to neurons49-52. Deshpande et al. 
showed that oligomers of AP bind to the synaptic contact and induce neuronal death, 
whereas amyloid fibrils need a higher concentration and a longer time span to produce 
the same toxicity level29. The authors also observed various species in an amyloid 
peptide solution: AP derived diffusible ligands (ADDLs, from trimer to higher 
molecular weight complex), AP oligomers (oligomers composed of 15-20 monomers), 
A*56 (dodecameric AP oligomers of 56 kDa)53, protofibrils (strings of oligomers) and 
fibrillar AP. Each of these species has its own specific toxicity on human corticon 
neurons. Among the oligomeric species, different toxicities can be observed as very 
small oligomers of mean particle size z  1-2 nm show increased binding to 
phospholipid vesicles and increased toxicity to neurons compared to those with 
z  4-5 nm. Monomers and fibrils did not even bind to the membrane54. The toxicity of 
AP seems to be correlated with the size of the oligomers: dimers are ? 3 times more 
toxic and tetramers ? 13 times more toxic55 than monomers. In parallel, A oligomers 
and ADDLs bind with high affinity to neuron cells, whereas much higher concentrations 
and longer incubation times were needed for A fibrils to lead to the same 
neurotoxicity29.  
 
b) Toxicity and structure 
Peptide structure appears to be of primary importance. It is directly linked to 
peptide oligomerization and, in turn, to its toxicity. As was explained above, the 
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protofibrils and fibrils are not toxic to the cells but rather the small oligomers.  Each 
species has a specific secondary structure: fibrils are mainly composed of cross -
sheets. ADDLs, in contrast, are mostly random-coil29.  
Therefore there could be a link between peptide secondary structure, toxicity 
and binding to the cell membrane. This hypothesis was expressed already in 1994 by 
Simmons et al., who could show that -sheet structure was linked to higher toxicity 
than random-coil56. The recent work of Shtainfeld et al. on human calcinotin (hCT), a 
fibril forming hormone peptide, goes into the same direction57. Various mutations in a 
hCT pentapeptide provided evidence for a correlation between the kinetics of fibril 
formation, lipid binding and amino-acid sequence. These experiments proved the 
importance of phenylalanine and methionine residues in lipid-induced fibrillization: a 
mutation of any of these amino-acids led to a change in the -sheet organization from 
parallel to anti-parallel arrangements. However the mechanism of the peptide toxicity 
is not understood yet.  
 
 
3. Aggregation model peptides  
Research on amyloid peptide aggregation is performed on wild-type peptides 
but also on models that allow isolation or induction of a specific property of the full-
length peptide and hence facilitate the study. Shorter sequences are often used as 
representations of the full-length peptide behavior and can allow a faster 
understanding of the studied phenomenon. This is the case, for example, for the 
human prion protein (PrP). PrP adopts a fibrillar structure whereas a model peptide, 
containing only 20 amino-acids of the full-length protein, forms stable oligomers. 
Although similar peptide packing was observed, long-range disorder and increased 
mobility distinguished the oligomers from the fibrils52.  
 
a) Designed model peptides 
In the past few years, newly-designed peptides were extensively studied as 
aggregation models.  These peptides are able to aggregate or undergo structural 
changes depending on similar parameters found relevant in fibril formation, such as 
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pH, salt concentration or the presence of metal ions. Pagel et al. conceived a peptide 
that could adopt either an -helical or a -sheet secondary structure58, similarly to 
amyloid-forming peptides, as a function of the presence of metal ions59. Similar 
peptides were designed by other groups to examine, for example, the interaction of 
amyloid peptides with hydrophobic surfaces60. The study of a modified amyloid 
peptide fragment proved that fibrils orient parallel to the membrane surface61. The use 
of a 12-mer peptide, derived from the full-length amyloid  peptide, enabled Makin 
and coworkers to perform X-rays on the peptide fibers and therefore define 
characteristics of antiparallel -sheets in a cross- arrangement62. As a last example 
the KIGAKI peptide, able to rapidly form -sheets63, helped determining the enthalpy 
of -sheet formation64.  
 
b) Amyloid fragments 
Shorter sequences of the amyloid peptide are often used as models, as they are 
sometimes easier to handle than the full-length amyloid peptide. The amyloidogenic 
AP(12-28)65 has the advantage of containing amino-acids supposed to be essential to 
aggregation66,67, although its ability to form long fibrils is not certain. AP(16-22) is one 
of the shorter fragments that is nevertheless able to form fibrils and is often used as -
amyloid model. Among its 7 residues, it contains the hydrophobic core suspected to be 
essential for the fibrillization of the full-length peptide68. Other fragments comprising 
various amino-acids of the whole sequence were studied, such as AP(10-35), AP(1-
28)69, AP(10-43), AP(10-23)70, AP(16-35)71 and many others72. All of these 
fragments possess the ability to form either aggregates or fibrils under specific 
conditions but usually show a better solubility in aqueous buffers than AP(1-40) or 
AP(1-42).  
 
c) Specific properties of AP(25-35)  
The fragment used throughout this work is AP(25-35). It contains an 
intramembrane part as well as an extracellular part. The fragment (25-35) is known to 
possess many of the characteristics of the full-length amyloid peptide. It has a highly 
hydrophobic amino-acid sequence, is prone to aggregation and, in contrast to most of 
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the other fragments studied, shows neurotoxic and neurotrophic activities73. 
Cytotoxicity of the peptide monomers could be proven with its effect on rat 
mitochondria74. This peptide is an attractive model to study not only the biophysical 
interaction of the amyloid peptide with the lipid membrane but also the physiological 
effect of amyloid peptide on neuron cells75-77.  
However, the high propensity to quickly form inhomogeneous aggregates in 
solution is an obstacle for the biophysical description of peptide aggregation, 
especially at neutral pH. An added difficulty in the study of AP(25-35) is the absence 
of a chromophore. This makes the determination of the peptide content difficult. For 
biophysical studies the precise knowledge of the peptide content is necessary. Once a 
suitable amyloid model peptide is defined, the membrane behavior itself needs to be 
understood.  
 
 
4. Lipids, membranes, and their role in protein aggregation  
Although lipid properties are well studied (from the thermodynamics of 
micellisation78, to lipid chains structural characterization79 or membrane curvature80), 
some features of well-known phenomena such as gel-to-liquid-crystal phase 
transition81 remain sometimes unexplained. Membrane structure and other properties 
are part of this study. 
 
a) The biological role of cellular membranes 
Biological membranes separate intracellular from extracellular space, but have 
also additional functional properties. They maintain a constant membrane potential, 
enable transmembrane ion transport, or allow membrane protein binding. The 
membrane prevents polar molecules (amino acids, carbohydrates, proteins) to diffuse 
through the membrane, whereas hydrophobic molecules and water can passively 
diffuse from the cytosol to the extracellular domain.  
Biological membranes are complex and highly structured macromolecular 
systems composed of a large number of lipid species and proteins. They are formed by 
a bilayer of amphiphatic phospholipids (glycolipids, steroids and phospholipids) and 
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contain diverse carbohydrates and proteins. The latter are responsible for the various 
activities of the cellular membrane. In some cases, the presence of lipids is an absolute 
prerequisite for the correct functioning of a protein. For example, the family of the 
protein kinases C (PKC) that play a major role in apoptosis, differentiation, mediation, 
needs phospholipid (usually phosphatidylserine) in order to phosphorylate diverse 
proteins82.  
 
b) Lipid bilayers as a model for the cellular membrane 
Phospholipid bilayers have attracted a great deal of interest because of their 
central role in cellular function and their potential as model bilayer systems in 
chemical and biological sensing applications. Phospholipids self-assemble 
spontaneously to form a bilayer structure with their hydrophobic tails directed toward 
the center, and their headgroups exposed to the aqueous phase83.  
The ability of lipids to self-assemble into fluid bilayer structures is consistent 
with two major roles in membranes: establishing a permeability barrier and providing 
a matrix for membrane proteins. Individual lipid components may play specific roles in 
establishing appropriate permeability characteristics, satisfying insertion and packing 
requirements for integral proteins, or facilitating the association of peripheral proteins. 
An intact permeability barrier for ions such as Na+, K+, and H+, is vital for establishing 
the electrochemical gradients which give rise to a membrane potential and drive other 
membrane-mediated transport processes. In addition, the lipids surround the 
membrane protein to seal it into the bilayer so that non-specific leakage is prevented. 
At the same time they provide an environment necessary for protein activity84. 
 
c) The importance of anionic lipids 
Most lipids present in biological membranes are zwitterionic or uncharged, but 
the less abundant anionic lipids are of great importance. Indeed a minimal amount of 
anionic lipids is required for cell growth and various other membrane functions. Van 
der Goot et al. showed the importance of negatively charged phospholipids in the 
channel formation of colicin A85. This pore-forming bacterial toxin kills Escherichia coli 
cells after binding to the specific receptors located in the outer membrane followed by 
translocation through the outer membrane and the periplasm. In vitro studies have 
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shown that negatively charged phospholipids are an absolute requirement for the 
channel formation of colicin A85. Dowhan and Xia demonstrated that anionic 
phospholipids are essential for the normal initiation of DNA replication by the DnaA 
protein86. The latter binds to the membrane via interaction with anionic 
phospholipids87. Negatively-charged lipids also play a role in the conversion of the 
inactive, ADP-bound DnaA protein to the active ATP bound form in vitro. It results in 
regeneration of the initiation activity of the DnaA protein88. 
 
d) Role of the lipid membrane in amyloid formation 
In the case of fibrillogenesis, the role of membranes is controversial. The lipid 
membrane is described by some groups as a catalyst32 for fibril formation, or as an 
obstacle to fibrillization by others38. Cell apoptosis could be due to ion channel 
formation89 or amyloid formation on the membrane surface disrupting the membrane 
and leading to lipid uptake involved in amyloid peptides cytotoxicity90. Amyloid 
formation is postulated to either decrease91 or increase92 membrane fluidity.  
AP(1-40) was shown to interact with negatively-charged membranes but not 
with uncharged surfaces93. The peptide undergoes a random-coil to -sheet lipid-
dependent conformational transition93 with the peptide adsorbed to the membrane 
surface94.  
Structural changes of the amyloid peptide are correlated with fibril formation 
and contribute to nucleation and aggregate stabilization. A careful thermodynamic 
study could provide information concerning the parameters controlling the system 
stability and peptide association. Previous biophysical studies93-96 established two 
possible ways of interaction between AP and the lipid membrane: either the peptide 
penetrates into the hydrophobic part of the lipid bilayer, or it aggregates at the surface 
of the bilayer. Following the structural changes of the lipid bilayer could help in 
understanding the aggregation mechanism and the peptide influence on the cell 
membrane. The gel-to-liquid crystal transition of the lipid bilayer is also known to 
influence protein activity97,98 and is a rather well-described phenomenon99,100.  
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II. Aims of research  
 
 
 
Amyloid peptide aggregation leads to plaque formation1,2, characteristic of 
more than 15 neurodegenerative diseases. The smaller oligomers are known to be the 
most toxic species to neuron cells3,4 however their interaction with cellular membrane 
is poorly understood. Biophysical studies with model membranes can provide insight 
into the peptide-membrane interaction with consequences for both peptide and 
membrane structure. The description of the amyloid fragment βAP(25-35) binding to 
lipid membrane is the main goal of this thesis. 
Biophysical studies performed on βAP(25-35) are very few and most of them 
were performed more than a decade ago. βAP(25-35) random-coil to β-sheet 
structural transition was first reported in 1994 and was shown to be concentration-
dependent and reversible5. The Chapter III of this thesis focuses on the reproduction of 
these data. 
βAP(25-35) is often used as a model peptide for the full-length amyloid β 
peptide, βAP(1-40), because the neurotoxic and neurotrophic activities and also the 
aggregation behavior of these two peptides are similar. However the low solubility of 
βAP(25-35) constitutes a major drawback in biophysical studies. Therefore the 
description of the peptide-to-lipid binding requires the synthesis of new model 
peptides. These model peptides should aggregate in the same way as βAP(25-35) but 
allow the precise determination of the peptide content (Chapter IV). 
In Chapter VI, the newly-designed model peptides are used for biophysical 
studies. The thermodynamic parameters such as enthalpy, entropy and free energy 
can be measured with isothermal titration calorimetry, a direct high-sensitivity 
technique which does not require any label. Peptide secondary structural changes 
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upon binding can be followed with circular dichroism experiments. Eventually solid-
state nuclear magnetic resonance (NMR) gives information on membrane structure. 
This information should allow the complete description of amyloid peptide binding to 
the lipid membrane. 
Phospholipids are commonly used as membrane models6 but some of their 
characteristics can still show unexplained particularities. The gel-to-liquid-crystal 
transition of phospholipids has been widely studied and its physical features such as 
melting temperature, viscosity or conductivity, have been characterized7,8. 
Nevertheless 1,2-dimyristoyl-glycero-3-[phospho-(1-glycerol)], DMPG, was shown to 
present a transition region, intermediate between the gel and liquid-crystalline 
state9,10, characterized by unusual physical properties11-13. The molecular structure of 
this intermediate phase has not been defined yet. Solid-state NMR study can help to 
determine DMPG structure in this transition region (Chapter X). 
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III. Structural study of AP(25-35) 
 
 
 
1. Introduction 
In the past years the amyloid peptide, AP(1-40), was extensively studied and 
various oligomeric species were observed in solution. The smallest oligomeric species 
studied are soluble and are called AP derived diffusible ligands (ADDLs). These 
oligomers have an aggregation range of 2 to 241. They may further aggregate to form 
dodecamers2, protofibrils1 and eventually fibrils3. As mentioned in the introduction, 
there seems to be a correlation between the secondary structure of each of these 
species and their toxicity4. However the analysis of the secondary structure of AP(1-
40) is difficult because of its low solubilization in aqueous buffers and the formation of 
aggregates.  
A common procedure to improve the solubility of AP(1-40) is a 
hexafluoroisopropanol, HFIP, pretreatment. This very polar, fluorinated alcohol favors 
the monomeric state of amyloid peptides in solution5. Other fluorinated solvents like 
trifluoroacetic acid produce similar solubilizing effect on amyloid aggregates5. The 
common procedure of HFIP pretreatment consists in dissolving the peptide in HFIP, 
and then evaporating the alcohol. The peptide can then be dissolved in buffer leading 
to a peptide solution free of aggregates. Other protocols try to further improve the 
peptide solubility by subsequent lyophilization6, or first dissolution in ammonia and 
then centrifugation of the sample7. A different procedure is to combine peptide 
dissolution with centrifugation, followed by column separation and dilution of the 
collected fractions in buffer8. Most of the latter procedures are inappropriate for 
biophysical use, either because the amyloid peptide carries with it fluorinated 
solvents9, or because the preparation protocol includes a filtration or centrifugation 
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step, and the peptide concentration cannot be determined precisely. HFIP treatment 
without any additional step is therefore currently the most suitable method for 
biophysical studies. Its use became common only in the past years, so the early 
biophysical studies on AP(1-40) did not include any peptide pre-treatment. 
Previous biophysical studies with amyloid peptides and their fragments 
revealed a random-coil to -sheet transition upon increase in concentration at pH 
4.010,11. They aggregate as anti-parallel -sheetsat pH 7.4 before forming-cross 
structures12,13. The structural changes undergone by the peptide and their kinetics can 
be influenced by environmental hydrophilicity14 and the presence of lipids12,15. In many 
cases -sheet formation is preceded by -helix formation16,17. This structural 
intermediate is suspected to play a role in fibrillization by facilitating -sheet 
formation18. The -helix intermediate was not seen yet in AP(25-35) fibrillization. The 
first part of this work focuses on the structural study of AP(25-35) and the detailed 
description of the random-coil to -sheet transition. The difficulties encountered 
during such a study will be discussed and the influence of the procedure used for 
peptide dissolution on the secondary structure evidenced.  
 
 
2. Materials and Methods 
The amyloid peptide AP(25-35) with the amino-acid sequence H-
GSNKGAIIGLM-OH (molecular weight of 1060.3 g.mol-1) was bought from Bachem (H-
1192). The peptide had a purity higher than 95%. 1,1,1,3,3,3-hexafluoroisopropanol 
(HFIP) was from Sigma-Aldrich (Schnelldorf, Germany). The buffers used were either 5 
or 10 mM HEPES at pH 7.4 (Roth, Karlsruhe, Germany) or sodium acetate, AcONa at pH 
4.0 (Merck, Darmstadt, Germany).  
 
Dissolution 1: Dry peptide was dissolved in buffer at 0.8 mg/mL (472 M, assuming 
that 40% of the powder is salt). It was stirred magnetically for 1-2 h to reach 
equilibrium between aggregates and soluble monomers. This stock solution was 
freshly prepared prior to the measurement. Subsequent dilutions were done in parallel 
from the equilibrated stock solution. The diluted solutions were also stirred for 1 h 
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before proceeding with the measurement. The CD signal was recorded on the 
equilibrated samples, starting with the low peptide concentrations. Peptide 
concentration was estimated from the stock solution. 
Dissolution 2: Dry peptide was dissolved in pure HFIP in order to get a 1.7 mg/mL stock 
solution (944 M, assuming that 40% of the powder is salt). It was vortexed and 
sonicated for 10 s in a water bath to ensure complete solubilization of the peptide. 
Each dilution was performed by drying the necessary amount of the stock solution in 
HFIP under a steam of nitrogen and then under high vacuum for 1 h before adding the 
desired buffer volume. This solution was again sonicated for 10 s to ensure complete 
solubilization of the peptide in buffer. Each dilution was stirred 20 min before the 
measurement. Peptide concentration was estimated by weight from stock solution. 
 
Circular Dichroism 
Circular dichroism measurements were performed on a Chirascan (Applied 
Photophysics Ltd., Leatherhead, UK) using 0.2 or 0.5 mm quartz cuvettes (Hellma, Jena, 
Germany). The experiments were started with 0.2 mm cuvettes but 0.5 mm cuvettes 
could be used at a later stage with improved instrumental settings. The bandwidth was 
set to 1.5 nm and the signal was recorded in 1 nm steps from 190-250 nm with an 
averaging time of 40 sec/point with the 0.2 mm cuvettes or 20 sec/point with the 0.5 
mm cuvette. All measurements were performed at room temperature. All spectra 
were corrected by subtracting buffer baseline.  
 
The output signal of the Chirascan is in millidegrees and is converted into mean 
residue ellipticity, []MR, expressed in deg. cm2.dmol-1 via the relation: 
 
AApeptide
MR nlc
CD510	  (1) 
with cpeptide the peptide concentration in mol.L-1, l the pathlength in cm and nAA the 
number of amino-acids of the peptide sequence. 
The secondary structure was analyzed by spectral fitting based on the linear 
combination of a CD spectra of peptide database19. 
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3. Results 
Based on the previous biophysical studies with AP(25-35)10,15, the dissolution 
procedure 1 was followed to dissolve dry AP(25-35) in buffer at pH 7.4. At this pH, the 
peptide is known to adopt -sheet secondary structure10. Figure 1 shows the structural 
changes of AP(25-35) upon peptide dilution.   
 
Figure 1: Concentration-dependent structural changes of AP(25-35) at pH 7.4. A 500 M 
AP(25-35) stock solution was prepared in 10 mM HEPES buffer at pH 7.4 and diluted. The 
estimated peptide concentrations are: 25 (___), 50 (___), 75 (___) and 102 M (___).  
 
Three of the spectra displayed in Figure 1 (25, 50 and 75 M) present similar CD 
characteristics. The mean residue ellipticity has a minimum at 215-218 nm and a 
maximum around 195 nm. This experiment was repeated by the same procedure and 
the reproducibility was low. For similar peptide dilutions, the CD spectra were different 
from those shown in Figure 1 (results not shown).  
The shape of the 25 M spectrum corresponds to -sheet features20,21 but the 
signal intensity is higher, evidence for a wrong estimated peptide concentration 
(Equation 1). In effect the peptide concentration can only be determined by weight 
because the molecule does not contain a chromophore. The presence of aggregates in 
the stock solution induces additional error. The incorrect peptide concentration leads 
to a spectral simulation of poor quality. Nevertheless the spectra in Figure 1 were 
analyzed as described in Materials and Methods (page 19); the best fittings are shown 
in Table 1.  
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Table 1: Secondary structure of AP(25-35) at pH 7.4 and 4.0. The -helix, -sheet, random-coil 
and -turn contents are expressed as percentage of the whole peptide secondary structure.  
The coefficient of determination R2 gives an indication on the quality of the fit. Only the 
concentrations leading to a reasonable fitting are represented here. 
 
 
 
Concentration -helix -sheet random-coil -turn R2 
(M) (%) (%) (%) (%) / 
pH 7.4 
 
50 2 98 0 0 0.95 
75 38 62 0 0 0.85 
102 63 31 6 0 0.96 
      
pH 4.0 
62.5 38 8 54 0 0.96 
125 59 38 3 0 0.97 
250 49 8 43 0 0.80 
500 92 0 8 0 0.96 
 
At 102 M, the secondary structure of AP(25-35) contains 31% -sheet. The -
sheet component is higher at 75 M (62%) and is further increased at 50 M where it 
contributes to 98% (R2=0.95) of AP(25-35) secondary structure. The presence of -
sheet at physiological pH is confirmed but its proportion in the various samples studied 
presents surprising features compared to the previous studies performed on the 
peptide. In effect Terzi et al. showed that the more AP(25-35) is concentrated, the 
more -sheet it forms10. The spectral analysis in Table 1 indicates another trend: -
sheet content decreases with increasing peptide concentration.  
 
At pH 4, Terzi showed that AP(25-35) undergoes a reversible and 
concentration-dependent random-coil to -sheet structural transition10. The results in 
Figure 2 represent the experiment performed to reproduce this transition. Dissolution 
procedure 1 was followed, starting from a 500 M peptide stock solution.  
The spectra at low peptide concentrations (15.5 and 62.5 M) are 
characterized by minima at 197 and 220 nm.  The spectral analysis (see Table 1) shows 
that random-coil is the dominant component at 62.5 M where it contributes to 54% 
of AP(25-35) secondary structure. -helix represents 38% of the peptide secondary 
structure at 62.5 M and the -helix contribution increases with AP(25-35) 
concentration.  The 500 M spectrum possesses clear -helix characteristics, with 
minima at 208 and 222 nm and a mean residue ellipticity []208 nm = -35.103 
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deg.cm2.dmol-1. The spectral analysis shows a -helix contribution of 92%. -sheet 
contribution is exclusively observed at 125 M where it represents 38% of the CD 
signal. However it is not the major component in contrast to what was expected from 
the literature10.  
 
Figure 2: Concentration-dependent structural changes of AP(25-35) at pH 4.0. A 500 M 
AP(25-35) stock solution was prepared in 5 mM AcONa buffer at pH 4.0 and diluted. The 
estimated peptide concentrations of the dilutions were: 15.5 (___), 62.5 (___), 125 (___), 250 
(___) and 500 M (___).  
 
a) The importance of the equilibration time in AP(25-35) structural study 
In Figure 2, the spectra at the three highest peptide concentrations (125, 250 
and 500 M) represent a -helical structure in pH 4.0 buffer. The literature describes 
the -helix secondary structure as an intermediate state in fibril formation16,22. It is 
further known that amyloid formation follows a seeding mechanism starting with a lag 
phase controlling nucleus formation23,24. Therefore increasing the equilibration time or 
giving supplementary energy to the system might enhance -sheet formation. The 
effect of stirring, heating and lengthening of the equilibration time was therefore 
investigated systematically. 
The CD spectrum of 500 M amyloid peptide solution was monitored over time 
and is shown in Figure 3. Two stock solutions were prepared according to dissolution 
procedure 1. One of them was stirred for only 1 h (Figure 3A), whereas the second 
stock solution was stirred up to 7 h, from peptide dissolution to sample monitoring 
(Figure 3B). Also the second stock solution was stirred at a 6°C higher temperature to 
accelerate further the structural transition in the second stock solution. The CD signals 
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of the peptide solutions were monitored at regular intervals. The experiment was 
stopped when no more variation in peptide secondary structure could be observed in 
the second sample.  
  
Figure 3: Structural changes of AP(25-35) at pH 4.0 over time. 500 M AP(25-35)  solution in 
5 mM AcONa buffer was kept at 23°C (A) without or (B) under stirring at 29°C. The samples 
were measured immediately (___), 2 h (___) and 7 h (___) after peptide dissolution.  
 
If highly-concentratedAP(25-35) is not continuously stirred (Figure 3A), no 
structural change is observed over 7 h. The peptide secondary structure remains 
constant, with the following contributions: 63% -helix and 37% random-coil 
(R2=0.91). -sheet formation was observed after a 24 h waiting period (results not 
shown). In comparison, AP(25-35) undergoes a clear structural transition from -helix 
towards -sheet over the same length of time upon additional stirring and heating 
(Figure 3B). The spectrum of AP(25-35) after 7 h under stirring and heating is 
composed of 54% -helix and 46% -sheet (R2=0.97). A similar experiment performed 
at room temperature showed a faster transition than without stirring but slower than 
with additional heating (results not shown). These experiments point out the influence 
of time, stirring, and heating in the study of amyloid peptide secondary structure.  
 
As the structural transition can be affected by the history of the sample, the 
experiment shown in Figure 2 was repeated with different stirring time. Figure 4A 
shows the concentration-dependent structural transition of AP(25-35) with samples 
measured after 30 min stirring and Figure 4B after 7 h stirring.   
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Figure 4: Concentration-dependent structural transition of AP(25-35) at pH 4.0 over time 
under stirring. The estimated peptide concentration was 15.5 (___), 31 (___), 62.5 (___), 125 
(___) and 500 M (___) and the samples were measured (A) after 30 min  or (B) after 7h of 
stirring.  
 
The comparison of Figure 4A and 4B shows that none of the sample studied has 
reached its final structure after 30 min equilibration. After 7h, only the two lower 
peptide concentrations seem to be at structural equilibrium since at 15.5 M, random-
coil is observed and at 31 M a transition from random-coil to -sheet occurs. Also the 
spectra in Figure 2 and 4A are different although the same procedure was applied. The 
peptide concentration was probably different in the two experiments but the peptide 
quantification is too inaccurate.  
 
b) The reversibility of the random-coil to -sheet structural transition 
The previous experiments showed that the stock solution reaches -sheet 
secondary structure only after several hours of stirring with additional heating. 
Consequently the dilutions in Figures 2 and 4 were prepared from a 500 M stock 
solution of -helix AP(25-35) and not of -sheet AP(25-35), as described earlier10. 
These experiments were thus proof of a reversible-helix to random-coil structural 
transition at pH 4.0, but not of a -sheet to random-coil transition.  
-sheet reversibility to random-coil was studied next. Using dissolution 
procedure 1, an equilibration of 24 h was allowed for the stock solution. After this 
period the peptide secondary structure was mostly -sheet. Next the stock solution 
was diluted and the dilutions were kept for 2h under stirring. CD spectra of selected 
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concentrations are represented in Figure 5. Longer stirring produced too much peptide 
adsorption on the vial walls.  
Figure 5: Concentration-dependent structural transition of AP(25-35) from a 500 M stock 
solution with the peptide as -sheet at pH 4.0. The peptide concentration was estimated at 10 
(___), 19 (___), 77 (___) and 308 M (___). 
 
The CD spectra at 308, 77 and 19 M are characteristic of -sheet. The mean 
residue ellipticity of the 10 M spectrum is too low to give indication on peptide 
secondary structure. This experiment was reproduced and -sheet was again observed 
over the whole concentration range, until the signal became too weak to allow any 
conclusion on the structural elements.  
In conclusion it seems that the major component of a diluted -sheet stock 
solution is still -sheet at pH 4.0. At low peptide concentrations where random-coil 
could be favored (between 15 and 30 M, see in Figure 4 and 10) the signal-to-noise 
ratio is too low. The present data provide no evidence for a -sheet-to-random-coil 
transition upon dilution at pH 4.0. 
 
c) The improvement in homogeneity of AP(25-35) solutions with HFIP  
As was mentioned previously, the estimated concentration by weight could be 
incorrect. Amino-acid analysis (AAA), before or after the spectroscopic measurement, 
can provide a precise knowledge of the peptide content of each sample. Unfortunately 
this facility is not available in our laboratories.  
Hexafluoroisopropanol, HFIP, pretreatment was tested for preparing AP(25-
35) solutions according to dissolution procedure 2. These peptide solutions should be 
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free of aggregates. Each diluted solution was freshly prepared starting from a stock 
solution of AP(25-35) in HFIP. After evaporation of the HFIP, each sample was diluted 
in buffer and stirred for 20 min prior to the spectroscopic measurement. The stirring 
times were therefore identical for each sample, contrary to the dissolution procedure 
1. The results of the monitored CD signals of amyloid peptide dilutions at pH 7.4 and 
pH 4.0 are shown in Figure 6. 
All spectra shown are characterized by a minimum mean residue ellipticity 
close to 195 nm. HFIP pretreatment favors the random-coil contribution in the 
secondary structure of AP(25-35) at both pH values. The weak minimum observed at 
217 nm indicates the presence of -sheet component. The CD signals variations 
observed at pH 7.4 can either indicate slight conformational changes or the presence 
of residual aggregates in solution. At pH 4.0, the spectra can all be perfectly 
superimposed, no structural change occurs over the concentration range studied.  
 
Figure 6: Concentration-dependent structural changes of HFIP-treated AP(25-35) at pH 7.4 (A) 
and pH 4.0 (B). The estimated peptide concentration was for (A) 25 (___), 47 (___), 79 (___), 117
(___) and 141 M (___) and for (B) 47 (___), 79 (___), 117 (___) and 141 M (___). 
 
 
4. Discussion 
This chapter points out the influence of experimental parameters on the 
structural properties of AP(25-35). Stirring or heating the samples favors nucleus 
formation23. The equilibration time needed to reach a new secondary structure is 
therefore shortened at a given peptide concentration. A similar mechanical effect is 
observed for interferon 
, INF-
 where dimers are the active form of the protein and 
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aggregation leads to inactivation of INF
25. Stirring was shown to induce the 
irreversible transition from the monomeric state, mostly -helical, to the aggregated 
state of INF-
, with reduced -helix content. Mechanical stress was investigated on 
AP(1-40) to evaluate the effect of shear stress and heating on the peptide secondary 
structure26. Dunstan et al. showed that amyloid fibrils are formed much faster upon 
stirring and heating26. They also compared the effect of stirring with shearing in 
Couette flow on AP, and concluded that shearing, rather than mixing, accelerates 
fibril formation. The exact mechanism leading to a decrease in the activation energy of 
aggregation upon shear stress is not known yet. Hill et al. investigated the effect of 
Couette flow on the aggregation of -lactoglobulin27. Their experiments showed the 
formation of globular aggregates under shear stress. However if amyloid aggregates, 
formed after 24 h incubation at 80°C, are put under shear stress, they disaggregate.  
 
The presence of aggregates in the solutions of AP(25-35) influences the shape 
of the CD spectra. It was Duysens who first published in 1956 that aggregates could 
cause signal distortions via light scattering and optical flattening28. A study published in 
1988 by Bastamante and Mastre29 gave the mathematical reasons for this 
phenomenon. If the big aggregates have a size comparable to the light wavelength 
(200 nm), they invalidate Beer’s law of light absorption. Therefore the absorbed light 
of a homogeneous sample differs from the one of an inhomogeneous sample at the 
same total concentration29.  
AP solutions can be homogenized with HFIP treatment. This alcohol is able to 
dissolve amyloid peptide aggregates30. The alcohol molecules may form hydrogen 
bonds with water molecules close to HFIP31. Therefore protein aggregates are 
surrounded by alcohol clusters that progressively disrupt them through hydrophobic 
interactions. Due to less ordered water molecules in the vicinity of the peptide, short 
distance interactions between amino and carboxy groups of amyloid peptides are 
enhanced what favors -helix stabilization30. This is the case when the peptide is 
directly dissolved in HFIP. In HFIP pretreated AP(25-35), the alcohol molecules are 
evaporated and the peptide is then dissolved in aqueous buffer (dissolution procedure 
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2). We show that HFIP pretreatment prevents the formation of aggregates and favors 
random-coil formation of AP(25-35) at both experimental pH values.  
 
In the present study we observe the formation of -helix as structural 
intermediate in the -sheet formation of AP(25-35) at pH 4.0. AP(25-35) aggregation 
process can be extended10 and described as follows: 
 
A reversible random-coil to -helix transition (see Figure 2) is followed by a -
helix to -sheet transition (see Figure 3B, 4B and 10). The -helix intermediate seems to 
be implicated in other amyloid peptides and fragments aggregation22,32,33. The -
helical intermediate is also necessary for AP(16-22) to form -sheets from random-
coil via hydrophobic and electrostatic interactions33. Abedini and Rayleigh proposed an 
aggregation process in which the initially random-coil amyloid peptides would contain 
an increasing -helix component that would favor interpeptidic interactions and 
therefore -sheet formation and further fibrillization18.   
 
 
III. Structural study of AP(25-35)  
 
29 
5. References 
(1) Walsh, D. M.; Lomakin, A.; Benedek, G. B.; Condron, M. M.; Teplow, D. B. J Biol 
Chem 1997, 272, 22364. 
(2) Lesne, S.; Koh, M. T.; Kotilinek, L.; Kayed, R.; Glabe, C. G.; Yang, A.; Gallagher, 
M.; Ashe, K. H. Nature 2006, 440, 352. 
(3) Lambert, M. P.; Barlow, A. K.; Chromy, B. A.; Edwards, C.; Freed, R.; Liosatos, 
M.; Morgan, T. E.; Rozovsky, I.; Trommer, B.; Viola, K. L.; Wals, P.; Zhang, C.; 
Finch, C. E.; Krafft, G. A.; Klein, W. L. Proc Natl Acad Sci U S A 1998, 95, 6448. 
(4) Kayed, R.; Head, E.; Thompson, J. L.; McIntire, T. M.; Milton, S. C.; Cotman, C. 
W.; Glabe, C. G. Science 2003, 300, 486. 
(5) Jao, S. C.; Ma, K.; Talafous, J.; Orlando, R.; Zagorski, M. G. Amyloid: Int. J. Exp. 
Clin. Invest. 4 1997, 240. 
(6) McLaurin, J.; Chakrabartty, A. Eur J Biochem 1997, 245, 355. 
(7) Matsuzaki, K.; Noguch, T.; Wakabayashi, M.; Ikeda, K.; Okada, T.; Ohashi, Y.; 
Hoshino, M.; Naiki, H. Biochim Biophys Acta 2007, 1768, 122. 
(8) Fezoui, Y.; Teplow, D. B. J Biol Chem 2002, 277, 36948. 
(9) Tomaselli, S.; Esposito, V.; Vangone, P.; van Nuland, N. A.; Bonvin, A. M.; 
Guerrini, R.; Tancredi, T.; Temussi, P. A.; Picone, D. Chembiochem 2006, 7, 257. 
(10) Terzi, E.; Holzemann, G.; Seelig, J. Biochemistry 1994, 33, 1345. 
(11) Chiti, F.; Dobson, C. M. Annu Rev Biochem 2006, 75, 333. 
(12) Terzi, E.; Holzemann, G.; Seelig, J. J Mol Biol 1995, 252, 633. 
(13) McLaurin, J.; Franklin, T.; Chakrabartty, A.; Fraser, P. E. J Mol Biol 1998, 278, 
183. 
(14) Shanmugam, G.; Jayakumar, R. Biopolymers 2004, 76, 421. 
(15) Terzi, E.; Holzemann, G.; Seelig, J. Biochemistry 1994, 33, 7434. 
(16) Kirkitadze, M. D.; Condron, M. M.; Teplow, D. B. J Mol Biol 2001, 312, 1103. 
(17) Jarvet, J.; Damberg, P.; Danielsson, J.; Johansson, I.; Eriksson, L. E.; Graslund, A. 
FEBS Lett 2003, 555, 371. 
(18) Abedini, A.; Raleigh, D. P. Phys Biol 2009, 6, 015005. 
(19) Reed, J.; Reed, T. A. Anal Biochem 1997, 254, 36. 
(20) Labhardt, A. M. J Mol Biol 1982, 157, 331. 
(21) Holzwarth, G.; Doty, P. J Am Chem Soc 1965, 87, 218. 
(22) Andreola, A.; Bellotti, V.; Giorgetti, S.; Mangione, P.; Obici, L.; Stoppini, M.; 
Torres, J.; Monzani, E.; Merlini, G.; Sunde, M. J Biol Chem 2003, 278, 2444. 
(23) Come, J. H.; Fraser, P. E.; Lansbury, P. T., Jr. Proc Natl Acad Sci U S A 1993, 90, 
5959. 
(24) Jarrett, J. T.; Lansbury, P. T., Jr. Biochemistry 1992, 31, 12345. 
(25) Zlateva, T.; Boteva, R.; Salvato, B.; Tsanev, R. Int J Biol Macromol 1999, 26, 357. 
(26) Dunstan, D. E.; Hamilton-Brown, P.; Asimakis, P.; Ducker, W.; Bertolini, J. 
Protein Eng Des Sel 2009, 22, 741. 
(27) Hill, E. K.; Krebs, B.; Goodall, D. G.; Howlett, G. J.; Dunstan, D. E. 
Biomacromolecules 2006, 7, 10. 
(28) Duysens, L. N. Biochim Biophys Acta 1956, 19, 1. 
(29) Bustamante, C.; Maestre, M. F. Proc Natl Acad Sci U S A 1988, 85, 8482. 
(30) Vieira, E. P.; Hermel, H.; Mohwald, H. Biochim Biophys Acta 2003, 1645, 6. 
(31) Israelachvili, J. Intermolecular and surface forces; Academic press, 1997. 
III. Structural study of AP(25-35)  
 
30 
(32) Hebda, J. A.; Saraogi, I.; Magzoub, M.; Hamilton, A. D.; Miranker, A. D. Chem 
Biol 2009, 16, 943. 
(33) Klimov, D. K.; Thirumalai, D. Structure 2003, 11, 295. 
31 
 
 
IV. Alzheimer model peptides for  
aggregation studies 
 
 
 
1. Introduction 
The previous chapter outlined the heterogeneity of AP(25-35) solutions due to 
aggregation. The low accuracy in the determination of the peptide concentration 
prevents the correct evaluation of thermodynamic data. Biophysical studies therefore 
require the design of related model peptides. These peptides should possess similar 
aggregation behavior as AP(25-35), form fibrils and allow an accurate determination 
of the peptide content.   
Peptide concentrations can be measured precisely by UV-absorbance. This 
requires peptides with chromophores, such as tryptophan or tyrosine. These amino-
acids have absorbance maxima at 280 and 275 nm, respectively, with the 
corresponding extinction coefficients Trp= 5500 M-1 and Tyr= 1490 M-1. The insertion 
of an amino-acid such as tryptophan, Trp, in the peptide sequence will therefore 
facilitate the concentration determination.  
The wild-type AP(25-35) sequence is: GSNKGAIIGLM and the appropriate 
position for Trp insertion needs to be defined. Some amino-acids are known to be 
essential for peptide aggregation and membrane binding. For example, the mutation 
of the Asn27 to Gln27 prevents amyloid formation of AP(25-35)1 despite the similarity 
of these amino-acids. The replacement of Ala30 by Ile30 in AP(28-35) has no effect on 
peptide conformation and fibril formation, whereas the mutation of Ala30 into Gly30 
prevents -sheet formation2. Lys28 and the C-terminal Met35 should not be modified 
because of the importance of electrostatic interactions in membrane binding of 
AP(25-35)3. Mutating the C-terminal Met35 to Ala35 decreases the hydrophobicity of 
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AP(25-35) and increases its toxicity4. Replacing or adding an amino-acid to the 
peptide sequence thus requires special care since peptide aggregation should not be 
prevented. 
 
Only few studies included Trp in the peptide sequences and little is known 
about the influence of this residue on peptide aggregation5-7. Trp fluorescence was 
used to monitor fibril formation and structural changes of AP(1-40). Fibril 
hydrophobicity was observed when Phe4 or Phe19 in AP(1-40) were replaced by Trp5. 
Trp in position 4 did not alter fibril formation or kinetics, whereas the substitution at 
position 19 lengthened the lag phase prior to nucleus formation5.  
The effects of Trp on the peptide-membrane interaction are better described 
and were particularly well-investigated in the field of antimicrobial peptides. Based on 
Trp fluorescence, it was observed that the residue is located preferentially in the lipid-
water interface7. The presence of Trp supports magainin toxicity6. Magainin is 
electrostatically attracted to the membrane and the preference of Trp for the lipid-
water interface increases the affinity of the peptide for the membrane8.  
 
In order to decide on the position of the Trp insertion for AP(25-35), the 
amino-acid sequences and their hydrophobicity were evaluated for the replacement of 
each amino-acid using the computing program TANGO9,10. The calculations are based 
on the physico-chemical properties of a peptide sequence that may influence 
aggregation namely hydrophobicity, energy of solvation, electrostatic interactions, and 
hydrogen bonding9. They result in the definition of a -sheet aggregation factor which 
increases with the aggregation propensity. Two peptide sequences containing Trp 
were selected. The Trp was added at position 24 in the first peptide, named WAP(25-
35), whereas in the second peptide named, AP(25-35)_I32W, Ile32 was replaced with 
Trp32. The calculated -sheet aggregation factors of the two designed peptides, at 
both neutral and acidic pH, are given in Table 1 together with their sequence.  
The calculation predicts a very similar aggregation behavior for WAP(25-35) 
compared to the wild-type peptide; the -sheet aggregation factors of the two 
peptides are identical. Trp addition at the N-terminal position does not seem to modify 
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the peptide aggregation behavior. In contrast, AP(25-35)_I32W seems to have 
reduced aggregation tendency and may be better solubilized.  
 
Table 1: Aggregation factors calculated at pH 7.4 and 4.0 for AP(25-35), WAP(25-35) and 
AP(25-35)_I32W. Their sequence is expressed in one-letter amino-acid code. The positively-
charged Lys is colored in yellow and the inserted Trp in blue. 
 
Sequence Designation Aggregation factor 
  pH 7.4 pH 4.0 
 
AP(25-35) 135.6 61.3 
WAP(25-35) 135.5 61.3 
AP(25-35)_I32W 60.7 24.8 
 
The ability of these two model peptides to aggregate will be investigated with 
light microscopy and dynamic light scattering, DLS. A fluorescence experiment with 
Thioflavine T will study their ability to form fibrils, a stacking of antiparallel -sheets. 
The secondary structure of the designed model peptides will be characterized with 
circular dichroism, CD, and compared to AP(25-35).   
 
 
2. Materials and Methods 
Peptides 
The wild-type amyloid peptide AP(25-35), H-GSNKGAIIGLM-OH, was bought 
from Bachem, Switzerland (H-1192). The solid-phase peptide synthesis of the analog 
AP(25-35)_I32W, H-GSNKGAIWGLM-OH, was initially performed but the peptide was 
difficult to separate from its derivative containing an aspartimide (see Appendix, page 
51). The analog AP(25-35)_I32W (molecular weight of 1133 g.mol-1) was therefore 
bought at Peptide 2.0 (Chantilly, USA). The analog WAP(25-35), H-WGSNKGAIIGLM-
OH, (molecular weight of 1247.5 g.mol-1) was ordered from AnaSpec (Fremont, USA). 
All peptides had a purity better than 95%. 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) 
was from Sigma-Aldrich (Schnelldorf, Germany). The buffers were either 5 or 10 mM 
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HEPES (Roth, Karlsruhe, Germany) at pH 7.4 or sodium acetate (AcONa, Merck, 
Darmstadt, Germany) at pH 4.0.  
The peptides were prepared following either dissolution procedure 1 or 2 as 
described on pages 20-21.  
 
Microscopic Imaging  
Microsocope images were recorded with an inverted microscope Nikon 
Diaphot TMD equipped with a high pressure mercury lamp (DC 100W USHIO) and CF 
objectives (x10: Ph L, Plan 4/0.13 DL; x20: Ph 1, Plan 10/0.30 DL).  
A 20 L droplet of peptide solution was deposited on siliconized glass of 1.8 cm 
diameter and covered with the same glass before observation.   
 
Ultra-violet spectroscopy 
The samples were monitored on a Uvikon 860 (GOEBEL Instrumentelle Analytik, 
Germany) with the buffer spectrum as a reference. A 1 cm cuvette was used (Hellma, 
Jena, Germany). Peptide concentration was determined from the absorption measured 
at 280 nm using Trp= 5500 M-1. The absorption spectra of WAP(25-35) and AP(25-
35)_I32W are shown below. 
  
Figure 2: Absorbance spectra of (A) WAP(25-35) and (B) AP(25-35)_I32W at pH 7.4. The 
peptide concentration was determined from the value of the absorbance at 280 nm at 35 M 
for WAP(25-35) and at 58 M for AP(25-35)_I32W.   
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Fluorescence 
Trp is known to emit fluorescence if excited at 280 nm. The fluorescence 
spectra of WAP(25-35) and AP(25-35)_I32W are shown in Figure 1. However Trp 
fluorescence did not allow us to monitor peptide aggregation, therefore the procedure 
described thereafter was used. 
The peptides were prepared in the same way as described above (Dissolution 1 
or 2). To the peptide powder or dried peptide film was added 395 L of buffer (10 mM 
HEPES at pH 7.4 or 10 mM AcONa at pH 4.0) and the solution was sonicated in a water 
bath for 10 s. The solution was transferred to a glass fluorescence cuvette (pathlength 
of 5mm, Hellma) and degassed with Argon. 5 L of Thioflavine T (Th T, Sigma, 
Schnelldorf, Germany) was added11. The solution was stirred during the whole 
measurement. The fluorescence spectra were recorded on a Jasco fluorimeter FP-6500 
(Gross-Umstadt, Germany), the bandwidth of both emission and excitation slit was 
3 nm and the scanning rate 50 nm/min. Every measurement was repeated twice and 
the spectrum of Th T in buffer was monitored to ensure no influence of the Th T alone 
on the observed signal. 
  
Figure 1: Fluorescence spectra of (A) WAP(25-35) and (B) AP(25-35)_I32W at pH 7.4. The 
peptide concentration was 45 M for WAP(25-35) and 98 M for AP(25-35)_I32W. The 
excitation wavelength was set at 280 nm.   
 
Dynamic Light Scattering measurements (DLS)
The size of the peptide aggregates were assessed by DLS on a Zetaziser (Nano 
Series NS, ZEN3600, Malvern Instruments Ltd, UK).  
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Circular Dichroism 
The CD measurements were performed in the way described previously on 
pages 21-22. 
 
 
3. Results 
a) Aggregation of the model peptides 
The aggregation behavior of the newly-designed model peptides can be readily 
observed by eye when diluting the model peptides into buffer. The dissolution of 
AP(25-35) in buffer at physiological pH and at ~ 100 M concentration leads to the 
formation of small oligomers, evidenced either as precipitates on the walls of the glass 
vial or as small flakes when gently agitating the solution. No precipitates or flakes can 
be detected by eye at pH 4.0 or when AP(25-35) is pretreated with HFIP. The same 
simple experiment was performed with the two model peptides. The solution of 
AP(25-35)_I32W appears to be clear both at pH 7.4 and 4.0, whether the peptide is 
pretreated with HFIP or not and no aggregates were observed by eye. This confirms 
the low peptide aggregation factor calculated earlier with TANGO (Table 1). In 
contrast, the dissolution of dry WAP(25-35) in buffer at pH 7.4 leads to the 
spontaneous formation of very large aggregates. At pH 4.0 without pretreatment and 
also at both pH if WAP(25-35) is pretreated with HFIP, no aggregates can be detected 
by eye. Visual observation agrees again with the aggregation factors in Table 1: 
WAP(25-35) and AP(25-35) have both a higher tendency to aggregate at pH 7.4 than 
at pH 4.0. In order to have a closer view of these aggregates, pictures of the various 
peptide solutions were taken under a light microscope (Figure 3).  
The pictures allow an estimate of the size of the aggregates formed in the 
various solutions. Pretreated or not, AP(25-35)_I32W forms only small oligomers 
ranging from 3 to 10 m at both pH values  (Figure 3C). In AP(25-35) and WAP(25-
35) solutions at pH 7.4, large heterogeneous oligomers are favored. In Figure 3A, 
AP(25-35) oligomers with size between 8 and 29 m are detected. The large 
aggregates of WAP(25-35) in Figure 3B are very thick and unstructured; their size 
varies between 22 and 110 m. If AP(25-35) and WAP(25-35) are pretreated or 
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dissolved as powder in pH 4.0 buffer, similar aggregates to the ones observed in 
Figure 3C are observed (results not shown).  
 
Figure 3: Pictures of aggregates observed for AP(25-35), WAP(25-35) and AP(25-35)_I32W 
in solution. (A) AP(25-35) and (B) WAP(25-35) were prepared at 230 M in HEPES pH 7.4 
following dissolution 1. (C) AP(25-35)_I32W at 230 M in AcONa pH 4.0 was prepared 
following dissolution 2. The black circles indicate representative aggregates. 
 
The aggregates shown in Figure 3 are observed at 230 M peptide 
concentration but the biophysical study will use HFIP-treated peptides at 
concentrations ranging down to 5 M. Studies in this lower concentration range 
require a different technique.  The appropriate technique for this purpose is dynamic 
light scattering (DLS) as it allows the observation of aggregates between 1 nm and 
1 m. The scattering intensity of the aggregate populations and their size are displayed 
in Figure 4.  
  
Figure 4: Size distribution of the aggregate populations by DLS in HFIP pretreated peptide 
solutions at (A) pH 7.4 and (B) pH 4.0. AP(25-35), WAP(25-35) and AP(25-35)_I32W are 
respectively (A) at 17, 9 and 3 M and (B) at 8, 12 and 6 M. The major population is depicted 
in green and the minor population in blue. The average size (in nm) of the composing 
aggregates is indicated on each bar. 
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AP(25-35) is composed of two aggregate populations both at pH 7.4 and 4.0 
but their proportions differ with the pH value. At pH 7.4, 530 nm particles account for 
67% of the light scattering, whereas 33% intensity is due to ? 80 nm particles. At pH 
4.0, the ? 80 nm particles are predominant (78%) and the ? 280 nm wide particles 
represent only 22% of the oligomers. WAP(25-35) forms aggregates of ? 90 nm (58%) 
and ? 400 nm (42%) size at pH 7.4. At pH 4.0, two oligomer populations of ? 70 nm 
(80%) diameter and of ? 480 nm diameter (20%) are observed. AP(25-35)_I32W is 
composed of ? 330 nm (57%) and ~ 55 nm (43%) wide particles at pH 7.4. Only one 
population of AP(25-35)_I32W aggregates is observed at pH 4.0, these particle are 
? 460 nm wide.  HFIP pretreatment does not lead to an exclusively monomeric 
solution. In most cases studied, at least two aggregate populations are observed.  
The DLS experiment provides an estimate of the size reached by the amyloid 
oligomers in the low concentration range studied. The size of the aggregates changes 
over time and the big aggregates tend to sediment. Therefore it is probable that the 
peptide solutions are constituted by a distribution of particles with a diameter ranging 
from 70 to 500 nm, or even larger diameters. It seems that the aggregates of AP(25-
35) and WAP(25-35) tend to be smaller at pH 4.0, in accordance with the aggregation 
factor given in Table 1. However AP(25-35)_I32W forms bigger aggregates at pH 4.0 
than at pH 7.4, which is in contrast to the TANGO predictions (see Table 1). These 
results show however that HFIP pretreated peptides aggregate at both pH values in 
this lower concentration range. The size of the measured particles is of the same order 
for each peptide. Only AP(25-35)_I32W forms bigger aggregates at pH 7.4 than the 
other two peptides studied. 
 
b) Fibrillization kinetics of the model peptides 
The ability of the designed peptides to form fibrils was studied following the 
protocol detailed in Materials and Methods (see pages 39-40). The time course of 
fibrillization can be followed by the change of Th T fluorescence and give indications on 
its kinetics. This widely used benzothiazole dye binds specifically to fibrils that form 
anti-parallel -sheet, without binding to monomeric or oligomeric intermediates11. The 
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binding mechanism of Th T to stacked -sheets is not understood yet. However the 
fluorescence intensity is proportional to the amount of amyloid fibrils formed11. The 
excitation of Th T at 450 nm results in fluorescence emission at 482 nm. Fibrillization of 
each of the three peptides was followed at pH 7.4 with a peptide concentration of 230 
M.  The results are shown on Figure 5.  
Figure 5A shows that the fluorescence intensity of Th T bound to AP(25-35) is 
higher than that induced by the two analogs. This disagrees with the imaging results 
(see Figure 3): the microscope pictures showed more and larger aggregates at pH 7.4 
for WAP(25-35) than for AP(25-35) and AP(25-35)_I32W. The magnification of the 
same data in Figure 5B shows that Th T bound to AP(25-35) and WAP(25-35) gives 
rise to similar fluorescence spectra. During the first 30 minutes of the experiment, a lag 
phase is observed and no fluorescence can be detected for both peptides. Following 
this waiting period, the fluorescence intensity starts to increase, indicating fibril 
formation. Maximum fluorescence intensity is reached after 120 and 50 min for 
WAP(25-35)and AP(25-35), respectively. After this fibrillization period, a gradual 
decrease of fluorescence intensity is registered until the end of the experiment (10-
20% decrease).  
  
Figure 5: Time course of Th T fluorescence in the presence of AP(25-35), WAP(25-35) and 
AP(25-35)_I32W at pH 7.4. (A) HFIP pretreated peptides at ?230 M were prepared following 
procedure 2. The evolution of ThT fluorescence alone (?), and in presence of AP(25-35) () , 
WAP(25-35) (), or AP(25-35)_I32W (?) are displayed. (B) Magnification of (A) showing 
ThT fluorescence in the presence of the analog peptides only. The experiment was repeated and 
a similar behavior was observed. A representative result is shown here. 
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The evolution of Th T fluorescence intensity in presence of AP(25-35)_I32W 
follows another trend. It starts at the maximum fluorescence intensity and the 
fluorescence keeps decreasing over the measuring period; a 60% decrease in 
fluorescence intensity is measured. The variations of Th T fluorescence in presence of 
the AP(25-35)_I32W is not characteristic of fibril formation. However the microscopy 
and DLS studies performed previously showed thatAP(25-35)_I32W and WAP(25-
35) aggregate (see Figure 3 and 4). The fluorescence study summarized in Figure 4 
does not allow their detection, or not to the expected extent. The aggregates observed 
in microscopy appear not to be assemblies of -sheet, or fibrils.  
 
c) Secondary structure of the model peptides in aqueous solutions 
The circular dichroism, CD, spectra of the two HFIP treated model peptides are 
displayed in Figure 6. All spectra show a minimum at 195-197 nm, characteristic of a 
random-coil structure. Yet the low mean residue ellipticity compared to a 100% 
random-coil spectrum implies the presence of another component. Details of the 
secondary structure can be obtained by spectral decomposition in terms of -helix, -
sheet, random-coil and -turn (Table 2).  
 
Table 2: Secondary structure component of the WAP(25-35) and AP(25-35)_I32W at pH 7.4 
and 4.0. -helix, -sheet, random-coil and -turn contents are expressed as percentage of the 
whole peptide secondary structure.  The coefficient of determination R2 gives an indication on 
the quality of the fit and is comprised between 0 and 1. Only the concentrations leading to 
reasonable fitting are represented here. 
 
 Concentration -helix -sheet random-coil -turn R2 
(M) (%) (%) (%) (%) / 
WAP(25-35), HFIP 
pH 7.4 
152 0 30 58 12 0.91 
354 0 27 61 12 0.97 
       
WAP(25-35), HFIP 
pH 4.0 
93 0 26 56 18 0.93 
157 0 28 53 19 0.79 
       
AP(25-35)_I32W 
pH 7.4 
69 0 32 62 6 0.97 
277 0 30 63 7 0.97 
554 0 29 60 11 0.98 
       
AP(25-35)_I32W 
pH 4.0 
22 0 28 56 16 0.99 
98 0 28 57 15 0.98 
407 0 30 58 12 0.97 
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The secondary structure of AP(25-35)_I32W at pH 7.4 is independent of the
peptide concentration: the spectra obtained at different concentrations are identical 
(Figure 6C). They are constituted by about 60% random-coil and 40% -content.  
At pH 4.0, an increase in AP(25-35)_I32W concentration induces an increase in 
the mean residue ellipticity (Figure 6D). A small increase of -sheet can be observed 
when AP(25-35)_I32W concentration increases (Table 2). The spectrum of AP(25-
35)_I32W at 11 M deviates from the others at higher wavelengths, which can be 
attributed to a lower signal-to-noise ratio.  
  
Figure 6: CD spectra of HFIP-pretreated WAP(25-35) at (A) pH 7.4  and (B) pH 4.0 and non-
treated AP(25-35)_I32W at (C) pH 7.4 and (D) pH 4.0. Peptide concentration was determined 
from tryptophan UV absorption at 280 nm in parallel to the CD measurement. 
WAP(25-35) was prepared following dissolution 2 in 5 mM HEPES at 37 (___), 63 (___), 152 
(___), and 354 M (___) (A) and in 5 mM AcONa at 29 (___), 93 (___), 137 (___), and 157 M (___) 
(B). AP_I32W prepared following dissolution 1 in 5 mM HEPES at 31 (___), 69 (___), 139 (___), 
277 M (___), and 554 M (___) (C) and in 5 mM AcONa at 11 (___), 22 (___), 46 (___), 98 M
(___), and 407 M (___) (D).  
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In contrast, the CD spectra of WAP(25-35) cannot be superimposed although 
they are very similar (Figure 6A and B). Slight structural changes are observed on the 
spectra that are not reflected in the structural analysis (see Table 2). Also the signal-to-
noise ratio is lower, decreasing the quality of the spectral analysis. However at pH 7.4, 
random-coil represents nearly 60% and -content 40% of the whole spectra. At pH 4.0, 
slightly less random-coil (55%) and more -structure (45%) are calculated. The CD 
signal of WAP(25-35) at pH 4.0 is positive at 225 nm. This positive contribution is also 
observed at pH 7.4, and at both pH values for AP(25-35)_I32W, but it is weaker. It can 
originate from the aromatic side chain of the Trp that was shown to have a 
contribution at 226 nm, similar to Phe12-14.  
 
The CD spectra of HFIP treated AP(25-35)_I32W give similar results to non-
treated AP(25-35)_I32W (see Figure 7), what agrees with the light microscope study. 
  
Figure 7: CD spectra of HFIP pretreated AP(25-35)_I32W at (A) pH 7.4 and (B) pH 4.0. The 
peptide concentration was determined from Trp UV absorption at 280 nm in parallel to the CD 
measurement. 
AP(25-35)_I32W was prepared following dissolution procedure 2 (A) in 5 mM HEPES at 46 
(___), 67 (___) ,and 77 (___) M  and (B) in 5 mM AcONa at 81 (___), 97 (___), and 251 (___) M .  
 
The CD spectra prove that the aggregates observed by light microscopy (Figure 
3) and DLS (Figure 4) have a -sheet contribution of ? 40%. The previously determined 
aggregation factor (Table 1) indicated a stronger tendency to aggregate at pH 7.4 than 
at pH 4.0 for all peptides. This trend is not observed in the CD experiments.  
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4. Discussion 
Aggregates could be observed by eye in the peptide solutions at 230 M and 
their size was evaluated with microscope imaging. It varies from 8 to 100 m. At the 
lowest concentrations (M range), the particles size measured with DLS ranged from 
70 to 630 nm. These results can be compared to the aggregates sizes listed in the 
literature. The size of oligomeric species is reported to range from 10 to 15 nm15, 
protofibrils are found with a diameter between 2.7 and 4.2 nm and a length of more 
than 100 nm16, while fibrils reach several micrometers in size. In the experiments 
shown previously at high peptide concentration (> 100 M), the particles observed 
have a similar size range as fibrils, although a fibrillar structure could not be confirmed 
and only unstructured aggregates were observed. In the lower concentration range 
(< 30 M), the small particles detected are probably protofibrils. These DLS 
experiments allow to conclude that the two model peptides aggregate to a similar 
extent as AP(25-35) under the same experimental conditions.  
Fibrillization was studied by Th T fluorescence. Despite the presence of 
aggregates in both model peptides solutions (Figure 3 and 4), Th T fluorescence in 
presence of the model peptides was much lower than with AP(25-35). In the case of 
WAP(25-35), binding occurs but it is very weak, compared to the propensity of the 
model peptide to aggregate (see Figure 3B). Considering the profile of Th T 
fluorescence in presence of AP(25-35)_I32W, it seems that Th T binding to this model 
peptide is unspecific. One of the explanations is that Th T binding to WAP(25-35) or 
AP(25-35)_I32W fibrils is hindered by the presence of Trp. It could also be that the 
aggregates of WAP(25-35) or AP(25-35)_I32W observed are amorphous and do not 
assemble in anti-parallel -sheets like AP(25-35).  
Although they occur in a different fluorescence intensity range, the time course 
of fibrillization of WAP(25-35) and AP(25-35) can be compared. For both peptides, a 
lag phase is observed17, followed by fibril formation. The fluorescence decrease 
registered at the end of the measurement is certainly due to the formation of larger 
aggregates. Their reduced availability in the solution11 lowers Th T affinity for the fibrils 
and decreases the fluorescence intensity registered. Part of the decrease in 
fluorescence can also be due to photobleaching.  
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CD experiments show that the three peptides studied have a similar secondary 
structure. Therefore the aggregates of WAP(25-35) and AP(25-35)_I32W observed 
in light microscopy and DLS are probably constituted by stacked -sheets similar to 
AP(25-35).  It can be concluded that the discrepancies observed between the three 
peptides with Th T fluorescence originate from a low affinity of the dye for the two 
model peptides due to the presence of Trp. Trp is slightly more polar and has a bulkier 
sidechain than Ile with its acyl side chain. The indole group could stick out of the 
stacked -sheets and prevent Th T interaction. This hindrance is less strong if the Trp is 
positioned at the N-terminal end of the peptide: the inner part of the stacked -sheet 
is still available for binding to Th T.  
 
Both WAP(25-35) and AP(25-35)_I32W aggregate with a similar secondary 
structure as AP(25-35). Due to the Trp chromophore, the concentration is accurately 
determined and can be excluded as a source of error. Consequently any mean residue 
ellipticity variation is likely to be caused by structural changes. WAP(25-35) and 
AP(25-35)_I32W are suitable model peptides to study AP(25-35) aggregation and 
interaction with the lipid membrane. 
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V. Appendix: Solid-Phase Peptide Synthesis of 
AP(25-35)_I32W  
 
 
 
1. Introduction 
Solid-phase peptide synthesis (SPPS) was introduced by Merrifield in 19631. It 
consists in the successive addition of protected amino-acids onto a polymer resin, 
often made of cross-linked styrene and divinylbenzene. The strategy of a resin-based 
synthesis provides the advantage that the resin is retained by a filter, whereas non-
reacted amino acids can be flushed through the filter. This results in a very rapid 
cycling of the synthesis steps. The steps of SPPS consist of the addition of activated and 
protected amino-acid onto the resin, its deprotection and subsequent coupling with 
the next protected amino-acid. A large choice of resins, amino acid protecting groups 
and activating reagents is available that afford different synthesis yields. Especially 
hydrophobic amino acids have a tendency to self-associate on the resin, so that 
reaction conditions must be optimized for each peptide of interest 2. 
Various research groups describe the synthesis of a fragment or the full-length 
AP(1-42). Most often, they report peptide aggregation on the resin due to the high 
hydrophobicity of the peptide caused by the high content in Ala, Ile, Gly, and Leu 3,4. 
These interpeptidic hydrophobic attractions disturb the coupling of subsequent amino-
acids by quite different means5. For example, on-resin aggregation influences the 
deprotection of the N-terminal end and thus often leads to final peptide mixtures of 
various lengths and compositions. Secondary reactions have been also reported for 
AP(1-42), such as N-O intramolecular acyl migration6,7 occurring especially for Ser, 
thus causing racemization reactions8,9 or reactions between the coupling agents. The 
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work below describes a first trial of the synthesis of AP(25-35)_I32W (amino-acid 
sequence GSNKGAIWGLM) and briefly proposes ways to further improve it. 
 
 
2. Materials and method 
a) Chemicals 
Fmoc-protected L-amino-acids, Met-loaded low density (0.2-0.4 mmol/g) Wang 
resin together with O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-
phosphate (HBTU) and hydroxybenzotriazol (HOBt) were bought from Nova Biochem 
(Merck). 1-methyl-2-pyrrolidon (NMP), N,N-diisopropylethylamine (DIEA), 
dimethylsulfid (DMS), tert-butyl-methylether (TBME), piperidine, acetonitrile and 
dichloromethane (DCM) were bought from Sigma-Aldrich (Schnelldorf, Germany). 
Tetrabuthylammonium iodide (TBAI), thioanisole, ethanedithiol and trifluoro acetic 
acid (TFA) were bought from Fluka. All solvents were of HPLC grade and were used 
without further purification.  
 
b) Peptide synthesis 
Solid-phase peptide synthesis of AP(25-35)_I32W was performed on an 
Applied Biosystems 433A (Rotkreuz, Switzerland). Amino-acid side-chain protecting 
groups were: triphenylmethane (Trt) for Asn and Ser, tert-butyloxycarbonyl (Boc) for 
Lys and pentamethyldihydrobenzofuransulfonyl (Pbf) for Arg. A starting quantity of 
0.1 mmol of resin was used, and the amino-acids were used in 10-fold excess. The 
Fmoc-protected amino-acids were activated with a 0.5 M HBTU/HOBt solution in DMF 
complemented with DIEA at 2 M in DMF. After resin rinsing, the coupled amino acids 
were deprotected with a 20% piperidine solution during 5 min.  
After completion of the synthesis, the resin-coupled peptide was washed with 
DCM and dried under high vacuum. The cleavage from the resin was made by a 
mixture of TFA/thioanisole/ethanedithiol/H2O/DMS/TBAI (85/5/3/3/2/2, v/v/v/v/v/v, 
5 ml) under protection with Argon10. After 2 h, the peptide was recovered from the 
resin and precipitated in cold TBME. The resin was washed with ~ 2 ml of cleavage 
solution. The peptide in TBME was centrifuged at 6°C for 30 min and 3000 rpm, 
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dissolved in 5 ml H2O and lyophilized. After lyophilization, the crude peptide was 
purified by reverse-phase HPLC (C8 column) and its purity was checked by analytical 
high-pressure liquid chromatography.  
 
c) Purification 
HPLC purification was performed on a Gilson instrument consisting of a 321 
pump associated with a diode-array spectrophotometer 8452A (Hewlett Packard). A 
Hibar pre-packed lichrosorb column RP 8 (250 x 25 mm, 7 m) was used, and the 
solvent consisted of a gradient of A: H2O and 0.1% TFA, B: acetonitrile and 0.1% TFA. 
The flow rate was set to 18 ml/min and the gradient of B was chosen from 5 to 80% 
within 75 min10. The peptide sequences were detected at 230 nm, 280 nm and 
300 nm, respective wavelengths of absorption of the peptide bond, Trp and Fmoc. The 
mass of the peptide was confirmed by MALDI-MS in a sinapinic acid matrix. 
 
 
3. Results and discussion 
The peptide was synthesized on a low density Wang resin. Its low grafting 
density resin reduced the risk for peptide aggregation. The HPLC of the crude peptide 
is shown in Figure 1. 
 
Figure 1: Elution profile of the synthesized peptide at 230, 280 and 330 nm. The absorbance 
traces are specific for Fmoc, the peptide bond and Trp (from bottom to top). 
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The right-hand shoulder of the main peak suggests that at least two peptides 
are present that are hardly separated by HPLC. A mass spectrometry analysis helped to 
identify the second peptide. Figure 2 shows the mass spectra of the mixture. 
MALDI confirmed the two peptides in their protonated form and as sodium 
adduct: AP(25-35)_I32W has a protonated molecular weight of 1135.1 g.mol-1 
(sodium adduct: 1157.1), and peptide X had a molecular weight of 1117.0 g.mol-1 
(sodium adduct 1139.0). The two peptides have a m/z difference of 18 g.mol-1 
suggesting the loss of water in the structure. This might be attributed to aspartimide 
formation 11 that is catalyzed by the use of strong bases in the synthesis 12,13,14. Peptide 
X is thus likely composed of the desired peptide AP(25-35)_I32W, where Asn27 
underwent cyclization.  
 
Figure 2: MALDI mass spectra of the synthesized peptide. The expected peptide is designed as 
AP(25-35)_I32W and the secondary product as X. Both peptides are present in their 
protonated and sodium adduct. 
 
 
In future attempts, this secondary product could be reduced by replacing 
piperidine by piperazine. Piperazine is a less nucleophilic deprotecting agent, but slows 
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down the deprotection reaction18. The higher peptide purity will thus be compensated 
by a lower total yield. Also the addition of phenols or hydroxybenzotriazole (HOBt) in 
the deprotecting solution8,18,19 might buffer amines and thus might reduce the Asn 
cyclization. Another possibility would be to replace the Trt protecting group of the 
amine in  of Asn27 by a bulkier group20,21 that would make the nuclophilic attack of 
the nitrogen atom in  more difficult.  
 
 
4. Conclusions 
The peptide synthesis of AP(25-35)_I32W yielded the peptide of interest to 
60%, but also a derivative of it because of aspartimide formation. The HPLC separation 
of the two peptides appears to be difficult because of their close hydrophobicity and 
molecular weight. Therefore future attempts must focus on optimization of the 
synthesis.  
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VI. Amyloid  peptide interaction with the
lipid membrane
 
 
 
1. Introduction 
Amyloid peptide neurotoxicity1,2 in Alzheimer’s disease involves interaction 
with the lipid membrane. Small oligomers of AP(1-40) are thought to create pores or 
ion channels in the membrane3-5 but the structural evidence in support of this 
hypothesis is weak. Alzheimer’s plaques are aggregates of AP(1-40) to (1-42) 
deposited on the cellular membrane6,7.  
Terzi et al. showed that the interaction of AP(1-40) and AP(25-35) with lipid 
membranes induces a random-coil-to--sheet structural change8,9. The authors also 
studied the thermodynamics of the binding of AP(25-35) to model membranes. They 
concluded that the interaction between the negatively-charged membrane and AP 
was essentially electrostatic in nature because no binding between AP(25-35) was 
observed in presence of high salt content.  
In the following study, we use high-sensitivity titration calorimetry to study the 
binding of AP(25-35), WAP(25-35) and AP(25-35)_I32W to model membranes at 
different temperatures and pH values. Special attention will be given to the effect of 
the inserted Trp on the binding mechanism. The changes of the secondary structure of 
each peptide upon binding to the lipid membrane will be followed with circular 
dichroism. Finally solid-state NMR experiments will be performed to investigate the 
structural changes of the lipid bilayer upon peptide binding.  
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2. Materials and Methods 
Peptides 
The amyloid peptide AP(25-35) with the amino-acid sequence H-
GSNKGAIIGLM-OH was bought from Bachem (H-1192). The mutant H-GSNKGAIWGLM-
OH was bought at Peptide 2.0 (Chantilly, USA). The mutant H-WGSNKGAIIGLM-OH was 
ordered from AnaSpec (Fremont, USA). All peptides had purity higher than 95%. 
1,1,1,3,3,3-hexafluoroisopropanol (HFIP) was from Sigma-Aldrich (Schnelldorf, 
Germany). The buffers used were either HEPES at pH 7.4 (Roth, Karlsruhe, Germany) or 
sodium acetate, AcONa, at pH 4.0 (Merck, Darmstadt, Germany) at 5 or 10 mM. 
Unless specified differently, the peptides were prepared following dissolution 
procedure 2 (see Chapter III, page 21).  
 
Lipids 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC, 850457C, molecular 
weight of 760.1 g.mol-1), 1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] 
(POPG, 840457C, molecular weight of 770.9 g.mol-1) and deuterated POPG, 1-
palmitoyl(d31)-2-oleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (860384C, molecular 
weight of 802.2 g.mol-1) in chloroform were ordered from Avanti Polar Lipids 
(Alabaster, USA).  
Small unilamellar vesicles (SUVs) of average size z = 50 nm, composed of 
POPC/POPG (3:1, mol/mol) were prepared as follows. The desired amount of POPC in 
chloroform was dried under a stream of nitrogen and then overnight under high 
vacuum. POPG in chloroform was added and the lipid mixture was vortexed and then 
dried as described for POPC. The desired amount of buffer was added and the 
dispersion vortexed. The multilamellar vesicles were sonified for 30 min under a 
stream of nitrogen (Branson sonifier S-250A equipped with a disruption horn, 200 W) 
until an almost clear dispersion of unilamellar vesicles was obtained.  
 
Circular Dichroism(CD) 
Circular dichroism measurements were performed on a Chirascan 
spectrophotometer (Applied Photophysics Ltd., Leatherhead, UK) using 0.5 mm 
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cuvettes (Hellma, Jena, Germany). The bandwidth was set at 1 nm, samples were 
measured every nanometer with an averaging time of 20 sec/point. The samples were 
scanned from 190 to 250 nm. All spectra were corrected by subtracting buffer baseline 
or the spectra of the SUVs in buffer.  
The lipid vesicles prepared by the above procedure were equilibrated with 
peptide under stirring for 20 min before the start of the CD measurement. Results are 
expressed in terms of ellipticity in units of deg.cm2.dmol-1. The conversion into mean 
residue ellipticity is performed as described in the Chapter III (page 21). The secondary 
structure was analyzed by spectral fitting based on the linear combination of a CD 
spectra of peptide database11. 
 
Dynamic Light scattering (DLS) 
The diameter of the small unilamellar vesicles (SUVs) was measured by DLS 
(Nano Series NS, ZEN3600, Malvern Instruments Ltd, UK) and their average size was 
about 50 nm at both pH values as shown in Figure 1.  
 
Figure 1: Size distribution for POPC/POPG SUVs (3:1) dispersed in 10 mM HEPES buffer at pH 
7.4. The average size z = 49 nm, and the peak width is 12 nm. 
 
This average size of POPC/POPG vesicles is larger than that of POPC SUVs with an 
average size z ? 30 nm. The presence of the negatively-charged POPG molecules and 
the low ionic strength of the buffer solution favor a slightly larger vesicle diameter. 
From the size of the SUVs and assuming a bilayer thickness10 of 4 nm, we can 
determine the outer membrane surface at 7855 nm2 and the inner surface membrane 
at 5540 nm2. This indicates a proportion of 59% of lipids that are accessible to the 
amyloid peptides for binding.  
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Isothermal Titration Calorimetry (ITC) 
Isothermal titration calorimetry was performed with a VP ITC instrument 
(Microcal, Northampton, MA). The cell volume was Vcell = 1.4037 ml. The peptide 
solution and lipid dispersion were degassed under vacuum and equilibrated at the 
experimental temperature for 10 min before filling the cells and syringe. The heats of 
reaction were corrected with the heat of dilution of POPC/POPG titrated into buffer. 
Raw data were processed using the Origin software provided by Microcal. 
 
Ultra-violet spectroscopy (UV) 
The samples were monitored on a Uvikon 860 (GOEBEL Instrumentelle Analytik, 
Germany) with the buffer spectrum as a reference. A 1 cm cuvette was used (Hellma, 
Jena, Germany). Peptide concentration was determined from the absorption measured 
at 280 nm. 
 
Solid-state Nuclear Magnetic Resonance (NMR) 
Solid state phosphorus NMR experiments were performed on a Bruker Advance 
400 MHz spectrometer (Bruker AXS, Karlsruhe, Germany). Spectra were recorded at 
162 MHz using a pulse-acquire sequence with broadband proton decoupling and a 
recycle delay of 6 s. The excitation pulse length was 10 s and 1000 FIDs were 
accumulated. The chemical shielding anisotropy, , was determined as the width at 
10% of the maximum intensity of the powder type spectra. 
Solid state deuterium NMR experiments were recorded at 61 MHz using a 
quadrupole echo sequence. The excitation pulse had a length of 5.5 s. 20 K FIDs were 
accumulated with a recycle delay of 250 ms.  
 
Preparation of NMR samples 
Peptides inserted into the membrane: 80 l (216 M) of peptide dissolved at 
1 mg/ml in HFIP, 7.5 mg (28 mM) of POPC and 250 l (9 mM) of d31-POPG at 10 mg/ml 
in chloroform were dried under a stream of nitrogen and then under high vacuum 
overnight. The film was dispersed in 10 mM HEPES in 2H-depleted H2O by vortexing in 
order to form multilamellar vesicles containing the peptide. 10 freeze-thaw cycles 
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were made to obtain homogeneous multilamellar vesicles. Each freeze-thaw cycle 
consists of three steps: freezing the sample at -80°C, warming it up to room 
temperature and vortexing it. The molar peptide-to-lipid ratio was 1:170.   
Peptides adsorbed to the membrane surface: Homogeneous multilamellar 
vesicles were prepared with 7.5 mg (28 mM) of POPC and 250 l (9 mM) of d31-POPG 
at 10 mg/ml in chloroform as described in the previous paragraph (Peptides inserted 
into the membrane). Eventually 800 M of dry peptide was added to the lipid 
dispersion and the mixture was vortexed. The molar peptide-to-lipid ratio was 1:50.     
 
  
3. Results 
a) Peptide binding to the membrane studied with ITC at pH 4.0 
Two types of titrations can be performed in ITC13,14: either the peptide solution 
is injected into the lipid dispersion, or the lipid vesicles are injected into the peptide 
solution. In the first case, as the lipids are much in excess compared to the peptide, all 
peptide molecules injected will bind to the lipid vesicles provided the binding constant 
is large. Each injection should give the same hi, and hi /ni will provide the enthalpy of 
binding, H0. This type of experiment cannot be performed in the case of the amyloid 
peptide. A high peptide concentration (? 100 M) is needed in the syringe to produce 
significant heat release and this would lead to aggregation before injection. Only the 
second type of experiment, i.e. titration of lipid vesicles into a peptide solution, could 
therefore be performed. Measurements were made at pH 4.0 and pH 7.4. The peptide 
concentration is also the limiting parameter in this type of experiment: it should not be 
too high, to avoid aggregation, but not too low in order to generate a significant heat 
release. A typical calorimetric heat flow trace obtained by titration of AP(25-35) with 
the negatively-charged POPC/POPG (3:1, mol/mol) SUVs is shown in Figure 2A. The 
binding between AP(25-35) and the model lipid membrane at 20°C and pH 4.0 is 
exothermic. At each injection, heat of reaction is released by binding of peptide to 
lipid. At each SUVs addition, the free peptide concentration is reduced and gives rise to 
lower heats of reaction, until all free peptide in the sample cell is bound. The residual 
heat is the heat of dilution of the lipid dispersion in the buffer.  
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Figure 2: Titration of 12.3 M AP(25-35) in 10 mM AcONa at pH 4.0 with 5.5 mM SUVs in the 
same buffer. Each injection is 10 l of POPC/POPG (3:1, mol/mol) suspension. The experiment 
was performed at 20°C. (A) Heat flow and (B) cumulative heat of reaction () as a function of 
the molar ratio of lipid to peptide. The theoretical binding isotherm (__) was calculated with the 
Gouy-Chapman theory combined with a surface partitioning equilibrium. The calculation 
assumes a binding constant K0 = 11 M
-1 and a peptide effective charge z = +2.  
 
The molar binding enthalpy H0 of amyloid peptide to POPC/POPG SUVs can be 
determined from the total heat released in the titration, i, and the molar amount of 
peptide in the sample cell, n0, according to: 
0
0
n
h
H i	  (1)
 
The integrated reaction heats are plotted against the molar lipid-to-peptide ratio in 
Figure 2B. The enthalpy of the reaction in Figure 2 is calculated according to Equation 
(1) with a total heat release of hi = -20 cal and assuming that the total amount of 
peptide in the calorimeter, n0 = 17 nmol, is bound. The calculation gives H0 =                 
-1.2 kcal.mol-1 (-5.0 kJ.mol-1). The experiment was repeated in the temperature range 
of 10 to 40°C. For each temperature the enthalpy is calculated from two independent 
measurements. The calculated binding enthalpies H0 are listed in Table 1. At all 
temperatures H0 was measured at about -1.38 kcal.mol-1 (-5.8 kJ.mol-1).  
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Table 1: Thermodynamic parameters for the binding of AP(25-35), and WAP(25-35) to SUVs 
composed of POPC/POPG (3:1, mol/mol) at various temperatures and pH 4.0. The data result 
from the average of two experiments and the standard deviation is indicated for the enthalpy 
and binding constant. The number of effective charges, z, is also indicated. 
 
 T 
(°C) 
H0 
(kcal/mol) 
K0 
(M-1) 
G0 
(kcal/mol) 
TS0 
(kcal/mol) 
z 
/ 
AP(25-35) 10 -1.42 ± 0.23 12 ± 0 -3.7 2.2 2 
 20 -1.37 ± 0.13 11 ± 0 -3.7 2.4 2 
 30 -1.36 ± 0.53 9.8 ± 0.4 -3.8 2.4 2 
       
WAP(25-35) 10 -7.18 ± 0.27 5 ± 0 -3.2 -4.0 2 
 20 -2.49 ± 0.75 4 ± 0 -3.2 0.6 2 
 25 -3.72 ± 0.52 4 ± 0 -3.2 -0.5 2 
 30 -2.26 ± 0.42 4 ± 0 -3.3 1.0 2 
 40 -3.71 ± 0.19 4.5 ± 0.7 -3.4 -0.3 2 
 
High-sensitivity calorimetric experiments can allow the definition of a binding 
isotherm15, Xib = f(cf). It describes the extent of binding, Xib, as a function of the 
concentration of free peptide, cf, at each injection of the titration. Xib is defined as the 
ratio between the molar amount of bound peptide, nipep bound, and the molar amount of 
injected lipid available for binding, niL, after i injections. 
i
L
i
boundpepi
b n
n
X ,	  (2)
 
nLi is given by the lipid concentration in the syringe, the volume of injection and the 
number i of injections performed. nipep,bound is determined from the experimental heats 
of reaction hi as follows: 
00
1
,
pepcell
k
i
k
i
boundpep cVH
h
n

	

	  (3)
 
with cpep0 the total peptide concentration in the calorimeter cell and Vcell the volume of 
the calorimeter cell. The molar amount of peptide bound to the lipid membrane 
(Equation 3) combined with the principle of mass conservation allows the calculation 
of the free peptide concentration in solution. This provides the description of the 
binding isotherm without assuming a specific binding model. Figure 3 shows the 
binding isotherm corresponding to the ITC measurement of Figure 2.  
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Figure 3: Binding isotherm of AP(25-35) derived from the ITC experiment shown in Figure 2. 
The experimental extent of bound peptide per lipid of the outer monolayer () is plotted versus 
the equilibrium concentration of free peptide in solution. The theoretical binding isotherm 
calculated with the Gouy-Chapman theory combined with a surface partitioning equilibrium 
(__) is represented. 
 
The calculation of further thermodynamic parameters such as the binding 
constant or the free energy of the reaction requires the analysis of the binding 
isotherm. In the present context it is based on a surface partitioning model in which 
the peptide binding to the lipid membrane is dependent on the peptide affinity for the 
lipid and the concentration of peptide, cM, found immediately above the plane of 
binding16,17 according to: 
Mb cKX 0	 (4)
 
with K0 the intrinsic binding constant. The surface partitioning model takes into 
account the attraction of positively-charged peptides to the negatively-charged 
membrane surface. The peptide concentration at the membrane surface, cM, is
therefore higher than the peptide concentration in the bulk, cf. The Boltzmann law 
expresses the electrostatic equilibrium between these two concentrations: 









 
	 RT
Fz
fM
p
ecc
0
 (5)
 
where zp is the peptide effective charge,  is the membrane surface potential, F0 is 
the Faraday constant and RT is the thermal energy. can be calculated from the 
Gouy-Chapman theory (see Appendix, page 91). It leads to the peptide concentration 
at the membrane surface after each lipid injection and finally to the intrinsic binding 
constant K0, according to equation (4). 
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The binding model also assumes that the peptide does not penetrate into the 
membrane. Only the outside layer of the lipid membrane is accessible for peptide 
binding. The outer surface represents about 60% of the total amount of lipid (see 
Materials and Method, page 59). The model also takes into account the binding of 
sodium cations to the negatively-charged POPG with a Langmuir adsorption isotherm, 
using a binding constant of 0.6 M-1. Finally at pH 4.0, an effective charge of +2 is 
attributed to the peptide. In effect, as the carboxyl end group is only partially 
protonated at acidic pH, the positive charge of the amino terminal end is not 
completely cancelled. The second charge is due to Lys28.  
 
The ITC data of AP(25-35) at each temperature were simulated with this 
model. As the heats of reaction were very small, not all experiments could be 
simulated. Only thermodynamic parameters based on a reasonable fitting are shown in 
Table 1.   
The intrinsic binding constants K0 of the reaction between AP(25-35) and 
POPC/POPG SUVs at pH 4.0 are rather low and vary between 10 M-1 at 30°C and 12 M-1 
at 20°C.  
The free energy of binding G0 follows from: G0 = -RTln(55.5 K0) and has a 
value of G0 = -3.7 kcal.mol-1 at 20°C (-15.5 kJ.mol-1). The factor 55.5 is the molar 
concentration of water and corrects for the cratic contribution. The binding entropy 
can be derived from the second law of thermodynamics, G0 = H0 -TS0 and TS0 = 
2.4 kcal.mol-1 at 20°C (10.0 kJ.mol-1). The theoretical binding isotherm of the titration 
at 20°C is shown in Figure 3. 
 
If the binding isotherm is expressed as a function of the free peptide 
concentration in the bulk, cf, an apparent binding constant, Kapp, is defined. The 
combination of equations (4) and (5) shows that Kapp is not constant, but that it varies 
with the surface potential, and therefore with the progress of the titration (see 
Equation 6). 
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Figure 4: Variations of the apparent binding constant of AP(25-35) to SUVs of POPC/POPG 
(3:1, mol/mol) with AP(25-35) concentration at the membrane surface in 10 mM AcONa at pH 
4.0.The change of Kapp () and the best fit based on the Gouy-Chapman theory (__) are 
represented. 
 
Figure 4 shows the decrease of Kapp with the concentration of free peptide in the cell.  
The apparent binding constant Kapp varies from 4802 M
-1 at cf = 11.0 M to 21096 M-1 
at cf = 0.8 M at 20°C. The large difference between the apparent and intrinsic binding 
constants shows the importance of the electrostatic forces during the binding of 
AP(25-35) to the lipid membrane.  
 
The two designed model peptides, WAP(25-35) and AP(25-35)_I32W were 
studied in the same way at pH 4.0. The titration curve of WAP(25-35) shows an 
exothermic profile, similar to the one of AP(25-35) (see Appendix). The values of the 
binding enthalpy H0 vary slightly around the mean binding enthalpy of                           
-3.04 kcal.mol-1 (-12.7 kJ.mol-1) between 20 and 40°C. These values are 2-fold higher 
than those measured for AP(25-35). The intrinsic binding constants deduced after 
calculation with the binding model vary slightly between 4 and 5 M-1 (see Table 1). 
These values are similar to the ones observed with AP(25-35). Kapp varies from      
4652 M-1 at cf = 6.4 M to 10040 M-1 at cf = 0.9 M at 20°C. The free energy is 
independent from the temperature and is close to -3.2 kcal.mol-1 (-13.3 kJ.mol-1). The 
thermodynamic parameters calculated at 10°C deviate from those between 20 and 
40°C. At lower temperatures, another binding mechanism could be involved. 
AP(25-35)_I32W showed an unusual ITC profile at lower temperatures. Two 
peaks are superimposed on the heat trace: one fast exothermic reaction followed by a 
slow endothermic process, as shown in Figure 5.  
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The calorimetric studies at higher temperatures showed exothermic profile 
similar to the ones observed for the binding of AP(25-35) or WAP(25-35). The heats 
of reaction were however too low to fit them with the binding model and the 
thermodynamic parameters could not be calculated. The ITC titrations measured 
between 10 and 35°C are shown in the Appendix.  
 
Figure 5: Titration of 3.7 M AP(25-35)_I32W in 10 mM AcON at pH 4.0 with 5.5 mM SUVs in 
the same buffer. Each injection is 10 l of POPC/POPG (3:1, mol/mol) suspension. The 
experiment was performed at 10°C. (A) Heat flow and (B) cumulative heat of reaction () as a 
function of the molar ratio of lipid to peptide. The inset illustrates details of the heat flow 
during the second injection. 
 
b) Peptide binding to the membrane studied with ITC at pH 7.4 
At pH 7.4 the ITC studies of AP(25-35) and WAP(25-35) showed low 
experimental reproducibility. Although the solutions of three HFIP-pretreated model 
peptides contained similar aggregate populations in DLS (Chapter IV), each sample of 
AP(25-35) and WAP(25-35) leads to a different calorimetric profile. The calorimetric
study was therefore performed exclusively with AP(25-35)_I32W at temperatures in 
the range of 10 to 30°C. A representative binding curve is shown in Figure 6. 
Similar to the experiments at pH 4.0, the reaction is exothermic and the heats 
of reaction were small. No agreement was found between the experimental data and 
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the model, consequently the thermodynamic parameters could not be calculated. The 
ITC titrations are shown in the appendix. 
 
Figure 6: Titration of a 5.2 M AP(25-35)_I32W in 10 mM HEPES at pH 7.4 with 5.5 mM SUVs 
in the same buffer. Each injection is 10 l of POPC/POPG (3:1, mol/mol) suspension. The 
experiment was performed at 30°C. (A) Heat flow and (B) cumulative heat of reaction () as a 
function of the molar ratio of lipid to peptide.  
 
c) Influence of the membrane surface charge on AP_I32W binding
The difference between K0 and Kapp observed at pH 4.0 indicates the importance 
of electrostatic forces in the binding of the amyloid model peptides to the lipid 
membrane. Thus the membrane surface charge certainly plays an important role in the 
binding mechanism. To investigate further the influence of the membrane surface 
charge, calorimetric studies were performed with AP(25-35)_I32W and POPC/POPG 
SUVs and varying the amount of the negatively-charged POPG.  
At pH 4.0, no heat of reaction can be measured in the calorimetric titration 
experiment of AP(25-35)_I32W with neutral POPC vesicles (results not shown). This 
absence of binding was already observed for AP(25-35)9. If the negative charge of the 
lipid membrane is increased (POPC/POPG 2:1, mol/mol), the binding of AP(25-
35)_I32W to the membrane leads to distinct heats of reaction. H0 varies between       
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-8.6 kcal.mol-1 at 15°C and -5.9 kcal.mol-1 at 30°C (-36 and -24.7 kJ.mol-1). The binding 
enthalpies of AP(25-35)_I32W to POPC/POPG (2:1, mol/mol) at pH 4.0 are 
summarized in Table 2. The ITC titrations performed between 8 and 40°C are shown in 
the Appendix.
 
Table 2: Thermodynamic parameters for the binding of AP(25-35)_I32W to SUVs composed of 
POPC/POPG (2:1, mol/mol) at various temperatures and pH 4.0. The data result from the 
average of at least two experiments and the standard deviation is indicated for the enthalpy 
and binding constant. The number of effective charges, z, is also indicated. 
 
T 
(°C) 
H0 
(kcal/mol) 
K0 
(M-1) 
G0 
(kcal/mol) 
TS0 
(kcal/mol) 
Cp 
(cal/mol/K) 
z
/ 
8 -8.50 ± 0.04 6.0 ± 0.7 -3.2 -5.3 
85 
R2=0.79 
2 
15 -8.60 ± 0.51 4.9 ± 0.1 -3.2 -5.4 2 
25 -7.87 ± 0.83 3.5 ± 0.1 -3.1 -4.8 2 
30 -5.97 ± 0.12 3.0 ± 0 -3.1 -2.9 2 
40 -6.39 ± 0.16 2.0 ± 0 -2.9 -3.5 2 
 
The molar heat capacity change Cp is determined from the variations of the 
binding enthalpy with the temperature18 from Cp = dH0/dT. H0 increases with the 
temperature and the slope of the regression line shown in Figure 7 indicates                    
Cp = 85 cal.mol-1.K-1    (356 J.mol-1.K-1). 
The intrinsic binding constants calculated with the binding model vary between 
6 M-1 at 8°C and 2 M-1 at 40°C. The free energy remains constant at a similar value to 
the one observed with less lipid charges (G0 -3.1 kcal.mol-1).  
 
Figure 7 	
	 

  H0 of AP(25-35)_I32W binding to POPC/POPG SUVs 
(2:1, mol/mol) at pH 4.0. The linear regression (__) gives the relationH0 = 0.0845 T- 9.4911                
(R² = 0.79). 
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At pH 7.4, POPG is fully-charged and increases further the membrane surface 
charge compared to the experiments at pH 4.0. The calculated parameters are shown 
in Table 3.  
 
Table 3: Thermodynamic parameters for the binding of AP(25-35)_I32W to SUVs composed of 
POPC/POPG (2:1, mol/mol) at various temperatures and pH 7.4. The standard deviation is 
indicated for the enthalpy and binding constant. The number of effective charges, z, is also 
indicated. 
 
T 
(°C) 
H0 
(kcal/mol) 
K0 
(M-1) 
G0 
(kcal/mol) 
TS0 
(kcal/mol) 
Cp 
(cal/mol/K) 
z 
/ 
12 -1.16 ± / 30 ± / -4.2 3.0  1.6 
15 -0.81 ± 0.10 30 ± 0 -4.3 3.4 38 
R2=0.73 
1.6 
20 -0.92 ± 0.06 25 ± 0 -4.2 3.3 1.6 
25 -0.55 ± 0.03 15 ± 0 -4.0 3.4  1.6 
 
Contrary to the previous experiment at pH 4.0, these ITC titrations show the 
release of very low heats of reaction. The binding enthalpies slightly increase from              
-1.2 kcal.mol-1 at 12°C and –0.6 kcal.mol-1 at 25°C (-5.0 to -2.5 kJ.mol-1). The intrinsic 
binding constant is 5-fold higher than at pH 4.0, with K0 = 30 M-1 at 12°C. The molar 
heat capacity is such as  Cp = 38 cal.mol-1.K-1 (159 J.mol-1.K-1) and the free energy 
remains constant around -4.2 kcal.mol-1 (-17.5 kJ.mol-1).  
 
d) Peptide binding to the membrane studied with circular dichroism 
The interaction between the negatively-charged lipids and the three amyloid 
model peptides was described with thermodynamic parameters at pH 4.0 for AP(25-
35) and WAP(25-35) and at pH 4.0 and pH 7.4 with increased membrane surface 
charge for AP(25-35)_I32W. Circular dichroism spectroscopy can be used to monitor 
the structural changes of the peptides upon lipid binding. AP(25-35) is known to 
undergo lipid-induced structural transitions9. A circular dichroism study of the peptide 
bound to lipid at various temperatures will allow the correlation between the 
thermodynamic parameters determined previously and changes in secondary 
structure. A first step is to observe the effect of the temperature on the peptides 
without lipids. This can then be compared to the effect of the lipid binding. Figure 8 
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shows the variations of the secondary structure of AP(25-35), WAP(25-35) and 
AP(25-35)_I32W at pH 4.0 from 10 to 40°C. 
  
 
Figure 8: Influence of the temperature on the secondary structure of the amyloid peptides in 10 
mM AcONa buffer at pH 4.0. HFIP treated (A) AP(25-35), (B) WAP(25-35), and (C) AP(25-
35)_I32W at ? 20 M. The scans were made at 10 (___), 20 (___), 30 (___), and 40°C (___).  
 
The CD spectra of all three peptides at pH 4.0 have a shape characteristic of 
random-coil, with a minimum ellipticity at 197-198 nm that decreases with the 
increasing temperature. Additionally the spectra of WAP(25-35) show contributions 
of the Trp24 at 225 nm19-21. The spectra were fitted as described previously (page 56). 
Although the shape of all spectra is characteristic of random-coil, the mean residue 
ellipticity of AP(25-35) and WAP(25-35) is smaller than expected for 100% random-
coil ([]MR(197nm) = -35000 deg.cm2.dmol-1). Therefore the fitting showed considerable 
deviation compared to the experimental data, with R2 values comprised between 0.75 
and 0.98, and can only be considered as an approximation. The fitting of AP(25-
35)_I32W is improved, with R2 close to 0.9. The random-coil content as evaluated for 
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AP(25-35), WAP(25-35) and AP(25-35)_I32W was 54, 57 and 89%, respectively, at 
10°C. At 40°C, the random-coil contribution decreases to 49, 53 and 80%, respectively. 
In parallel, the -sheet content increases from 25 to 33% for AP(25-35) and from 25 
to 31% for WAP(25-35). Contrary to AP(25-35) and WAP(25-35), the secondary 
structure of AP(25-35)_I32W does not contain any -sheet component. 
 
 Figure 9 shows the variations in secondary structure of AP(25-35), WAP(25-
35) and AP(25-35)_I32W at pH 7.4 from 10 to 40°C. 
  
 
Figure 9: Influence of the temperature on the secondary structure of the amyloid peptides in 10 
mM HEPES buffer at pH 7.4. HFIP treated (A) AP(25-35), (B) WAP(25-35), and (C) AP(25-
35)_I32W at ? 20 M. The scans were made at 10 (___), 20 (___), 30 (___), and 40°C (___).  
 
At pH 7.4, the shape of the spectra contains features of random-coil, yet the 
mean residue ellipticity is smaller, similar to the experiment at pH 4.0. The CD spectra 
are also characterized by a minimum ellipticity at 197 nm. The mean residue ellipticity 
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tends to decrease with the increasing temperature in the case of AP(25-35) and 
AP(25-35)_I32W but this is not true for WAP(25-35). The spectral fitting of all 
spectra is of poor quality (R2 values close to 0.85) and the slight spectral changes 
observed in Figure 9 for AP(25-35) and AP(25-35)_I32W are not represented by the 
analysis. At 10°C, AP(25-35) is composed of 26% -sheet, 53% random-coil and 21% 
-turn. This composition is almost unchanged at 40°C (29, 52 and 19%, respectively). 
The secondary structure of AP(25-35)_I32W determined by fitting is also similar at 
the two temperatures, and is composed of about 32% -sheet, 41% random-coil and 
17% -component. However an exchange between -structure and random-coil occurs 
in the secondary structure of WAP(25-35) upon temperature increase: 32% -sheet, 
41% random-coil and 17% -turn at 10°C and   22% -sheet, 65% random-coil and 6% 
-turn at 40°C.  
 
The peptide structural changes upon lipid binding are investigated next. The 
peptide-to-lipid ratio was adjusted to match the end of the calorimetric titration. This 
ratio varies from 1/50 to 1/100 in the calorimetric experiment (see Figure 2 and 6). In 
order to ensure complete peptide binding, the CD experiments were made at a 
peptide to lipid ratio P/L ? 1/120. Amyloid peptide concentration and the scattering 
caused by the SUVs are the limiting factors in this experiment. A minimal peptide 
concentration of 20-30 M is necessary for a good signal-to-noise ratio. The maximum 
lipid concentration used was 2.5 mM in order to minimize the scatter. CD spectra were 
recorded between 190 and 250 nm.  
The results obtained for the structural study at acidic pH are shown in Figure 10. 
Bound AP(25-35) and WAP(25-35) have CD spectra with a shape and a minimum 
mean residue ellipticity close to -30000 deg.cm2.dmol-1, features of random-coil, yet 
the minimum ellipticity is slightly shifted at 200 and 203 nm, respectively. The spectra 
of these two bound peptides do not change with the temperature. The fitting (R2 = 
0.95 for bound AP(25-35), and R2 = 0.85 for bound WAP(25-35)) confirms that both 
peptides are mostly in a random-coil structure, which is independent of the 
temperature (89% and ? 72%, respectively). The -helical content is 11 and 28%, 
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respectively. In contrast, the spectra of bound AP(25-35)_I32W show two minima: 
one at 203 nm,  at a mean residue ellipticity close to -13000 deg.cm2.dmol-1, and the 
second at 218 nm, indicating the additional contribution of -sheet. Upon temperature 
increase, the mean residue ellipticity at 203 nm decreases in favor of the mean residue 
ellipticity at 218 nm. The spectral fitting (R2 = 0.75) shows that at 10°C random-coil is 
dominant (57% against 15% -helix and 28% -sheet) whereas higher temperatures 
favor -sheet formation (40% random-coil, 15% -helix and 45% -sheet at 40°C).   
  
 
Figure 10: Influence of the temperature on the secondary structure of the three peptides bound 
to lipid at pH 4.0. HFIP treated (A) AP(25-35), (B) WAP(25-35), and (C) AP(25-35)_I32W. To 
a peptide solution (~ 20 M) was added POPC/POPG SUVs (3:1, mol/mol) at a 1/120 ratio. The 
scans were made at 10 (___), 20 (___), 30 (___), and 40°C (___).  
 
Figure 11 shows the structural study of the three peptides at neutral pH value. 
The shape of the CD spectra of bound AP(25-35) has characteristics of random-coil 
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and -helix. The spectra have a minimum at 201 nm that shifts towards 203 nm upon 
temperature increase, and a second minimum at 222 nm. The spectra of bound 
WAP(25-35) and AP(25-35)_I32W show a minimum at 204 nm and an additional 
contribution at about 219 nm. The mean residue ellipticity observed at about 204 nm 
for the three model peptides decreases upon temperature increase.  
  
 
 Figure 11: Influence of the temperature on the secondary structure of the three peptides 
bound to lipid at pH 7.4. HFIP treated (A) AP(25-35), (B) WAP(25-35), and (C) AP(25-
35)_I32W. To a peptide solution (? 20 M) was added POPC/POPG SUVs (3:1, mol/mol) at a 
1/120 ratio. The scans were made at 10 (___), 20 (___), 30 (___), and 40°C (___).  
 
The spectral fitting indicates that the three bound peptides tend to increase the 
contribution of -sheet in their secondary structure upon temperature increase (R2 ? 
0.75). Random-coil is the principal structural component at low temperature 
(respectively for AP(25-35), WAP(25-35) and AP(25-35)_I32W: 75, 55 and 64%) and 
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is converted into -sheet (17, 22 and 40%) at 40°C. Only AP(25-35)_I32W contains 
already 28% -sheet at 10°C. 
 
The comparison of the CD spectra of the peptides bound to the lipid membrane 
(Figure 10 and 11) with the CD signal of each unbound peptide (see Figure 8 and 9) 
enables to extract the effect of temperature, lipid binding and pH on the peptide 
secondary structure. The change in secondary structure of each peptide is summarized 
in Figure 12.  At both pH, lipid binding has a strong influence on the secondary 
structure of AP(25-35) and WAP(25-35) since it removes or reduces -sheet content 
in favor of random-coil and -helix components. Only at pH 7.4 and 40°C, -sheet is 
observed in AP(25-35) and WAP(25-35), but its proportion is smaller than in the 
unbound peptides. In contrast, the secondary structure of unbound and bound 
AP(25-35)_I32W are similar at pH 7.4, whereas at pH 4.0, lipid binding induces -
structure formation in AP(25-35)_I32W.  
 
Figure 12: Representation of the structural content of the three amyloid model peptides at pH 
7.4 or 4.0 and at 10 or 40°C. AP(25-35), WAP(25-35) and AP(25-35)_I32W are represented, 
unbound or bound to the lipid membrane. The secondary structure considers random-coil, -
sheet, -turn and -helix content. It is expressed as percentage of the whole peptide structure.  
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e) Peptide binding to the membrane studied with by solid-state NMR 
The previous CD experiments indicate structural changes of the amyloid model 
peptides upon binding to the lipid membrane at both pH 7.4 and 4.0. The binding of 
peptide to the lipid surface can also influence the lipid phase. It can affect the 
membrane stability, thereby influencing the gel-to-liquid crystal transition 
temperature. Other effects are a change in the long-range organization of the lipid 
phase upon peptide association; for instance, the bilayer can be converted into a 
hexagonal or micellar phase22,23. The next step of this study focuses on lipid structure, 
lipid motions and phase behavior using solid-state nuclear magnetic resonance (NMR), 
either by looking at the phosphorus 31P- or deuterium 2H-NMR spectra (see Appendix, 
page 99). In a first type of experiment, the amyloid model peptides were co-dissolved 
with lipids and dried. Upon hydration the peptides inserted into the multilamellar 
vesicles. In a second type of experiment, the effect of the association of amyloid 
peptide aggregates with the preformed lipid multilamellar vesicles was investigated.  
Figure 13 shows the 31P-NMR spectra of the lipid vesicles after insertion of the 
amyloid model peptides, for temperatures between -10°C and 40°C. In this study, the 
peptide-to-lipid ratio was 1/170, in order to match the CD and ITC measurements 
performed previously. All spectra of POPC and d31-POPG vesicles are characteristic of 
lipid bilayers either in the gel or in the liquid-crystalline state. Both POPC and d31-POPG 
have their own specific chemical shift in the applied magnetic field. Therefore two 
high-intensity peaks can be distinguished at +12 and +16 ppm in the spectra of the lipid 
vesicles without peptide at higher temperatures (Figure 13A). This observation is also 
made when AP(25-35)_I32W is inserted into the membrane (Figure 13D) at the same 
chemical shifts. However, if AP(25-35) or WAP(25-35) are inserted into the lipid 
membrane (Figure 13B and 13C), the high-intensity shoulders of POPC and d31-POPG 
are merged into a broad peak at +14 and +12 ppm respectively. Furthermore in the 
presence of AP(25-35), the intrinsic linewidth is much broader in the liquid-crystalline 
phase (Figure 13B) compared to WAP(25-35) or AP(25-35)_I32W. The negative 
curvature observed in the spectra of the pure lipid membrane (Figure 13A) at the 
higher temperatures could be due to insufficient lipid hydration.  
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 Figure 13: 31P-NMR spectra of POPC/d31-POPG (A) without, and with (B) AP(25-35), (C) 
WAP(25-35)  and (D) AP(25-35)_I32W inserted at a peptide-to-lipid ratio of 1/170. The 
amyloid model peptides and the lipid mixture were dissolved in chloroform and dried. 10 mM 
HEPES in deuterium-depleted water was added to give a final peptide concentration of 216 M. 
The spectra were recorded from bottom to top (A) -10, -2, 0, 2, 10, 20, 30 and 40°C, (B)  -10, -8, 
-6, -2, 0, 2,4, 6, 8, and  10°C, (C) -12, -10, -8, -6, -4, -2, 0, 2 and 4°C , (D) -10, -7, -4, -2, 0, 2, 4, 6, 
8 and 10°C. The inset in A shows a theoretical bilayer spectrum. 
 
The anisotropic motions of the phosphate group were quantified with the 
chemical shielding anisotropy, 	??.  can be measured on the 31P-NMR 
spectrum as full-width at 10% of the maximal intensity (see Appendix, page 99). Its 
variations with the temperature are displayed in Figure 14. Below 2°C,  of the pure 
lipid vesicles is almost constant at -77 ppm (Figure 14). At higher temperatures, the 
phosphate group undergoes a fast rotation and the edges of the 31P-NMR spectra are 
better defined (see Figure 13).  increases to -54 ppm. The inflection point in the 
variations of the chemical shielding anisotropy denotes the transition temperature, Tm, 
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of POPC and d31-POPG bilayers.  It reveals a phase transition of the lipids at 2°C. This 
value is higher than the data available in the literature, Tm = -2°C, determined from 
calorimetric measurements24,25. When any of the model peptides is inserted into the 
lipid vesicles,  in the liquid-crystalline phase varies from -53 to -46 ppm, depending 
on the peptide considered. At lower temperatures,  is close to the value of the pure 
lipid bilayer when WAP(25-35) is inserted, reaching a plateau at about -80 ppm at low 
temperatures. In contrast, after insertion of AP(25-35),  increases to -70 ppm, 
whereas the insertion of AP(25-35)_I32W induces a decrease to   = -90 ppm. The 
insertion of any of the peptides shifts Tm towards lower value. The Tm of AP(25-35), 
WAP(25-35) and AP(25-35)_I32W determined from Figure 14 are -1, -4 and 0°C, 
respectively.  
 
Figure 14: Chemical shielding anisotropy  of POPC/d31-POPG as a function of the 
temperature. Amyloid model peptides were co-dissolved with lipid in organic solvent, dried, and 
suspended in buffer.  values are calculated from solid-state NMR spectra (Figure 13).  of 
POPC/d31-POPG alone ( ?) and with the insertion of AP(25-35) ( ??), WAP(25-35)  ( ?) or 
AP(25-35)_I32W ( ??). 
 
Figure 15 shows the 2H spectra of the lipid membrane alone and after insertion 
of the three amyloid peptides. The spectra result from a superposition of quadrupole 
splittings, Q, of all deuterons on the POPG lipid chain. Each deuteron gives rise to a 
splitting, the size of which varies with the position of the deuteron along the chain. The 
spectra are characteristic of lipid bilayers either in the gel or in the liquid-crystalline 
state. One spectrum on Figure 15B is however different from all others. A particular 
behavior of the acyl chains is observed at 20°C upon insertion of AP(25-35): an 
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isotropic phase, or a total loss of signal, is present in addition to the bilayer phase. This 
isotropic phase is not observed at any other temperature.  
 
Figure 15: 2H-NMR spectra of POPC/d31-POPG (A) alone, and with (B) AP(25-35), (C) WAP(25-
35)  and (D) AP(25-35)_I32W inserted at a peptide-to-lipid ratio of 1:170. The amyloid model 
peptides and the lipid mixture were dissolved in chloroform and dried. 10 mM HEPES in 
deuterium-depleted water was added to give a final peptide concentration of 216 M. The 
spectra were recorded from bottom to top at (A) -10, -2, 0, 2, 10, 20, 30 and 40°C, (B) 0, 2, 4, 
10, 20 and 30°C, (C) 0, 2, 4, 10, 20 and 30°C, (D) -10, 0, 2, 4, 10, 20, 30 and 40°C.  
 
The variations of the outermost quadrupole splitting with the temperature are 
plotted in Figure 16A. The quadrupole splitting at low temperature could not be 
determined for the lipid vesicle without peptide or with AP(25-35)_I32W due to a low 
signal-to-noise ratio.  
Above -2°C the spectra of the pure lipid membranes are characterized by 
Q(CD2) = 27 kHz. With any of the model peptides inserted, Q(CD2) follows similar 
variations and remains close to 25 kHz. Below 4°C, Q(CD2) of the vesicles containing 
AP(25-35) or WAP(25-35) reaches a plateau at 36 kHz. 
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Figure 16: (A) Quadrupole splitting Q(CH2) and (B) Q(CH3) of POPC/d31-POPG as a function of 
the temperature. Amyloid model peptides were co-dissolved with lipid in organic solvent, dried, 
and suspended in buffer. Q are calculated from solid-state NMR spectra (Figure 15). Q of 
POPC/d31-POPG alone ( ?) and with the insertion of AP(25-35) ( ?? ), WAP(25-35) ( ?) or 
AP(25-35)_I32W ( ??). 
 
The innermost quadrupole splitting observed for the spectra of Figure 15 can 
be assigned to the terminal CD3 group of the acyl chain, Q(CD3). The temperature 
dependence of Q(CD3) is shown in Figure 16B. Q(CD3) of the pure lipid membrane 
reaches an upper plateau at Q(CD3) = 13 kHz below -3°C and a lower plateau at 4 kHz 
above this temperature. The lower plateau remains between 4 and 5 kHz also after 
insertion of the model peptides. In contrast, Q(CD3) increases to 15 kHz below -3°C 
with the three peptides inserted.  
The phase transition of the pure lipid membrane can be defined at -3°C for the 
lipid chains, which is closer to the value reported in the literature24,25. The phase 
transition of the lipid chains of the vesicles containing AP(25-35), WAP(25-35) or 
AP(25-35)_I32W occurs at 4°C.   
Our results on peptide insertion are similar to the ones reported in the 
literature, based on 13C or 31P MAS NMR experiments26,27 for a peptide-to-lipid ratio of 
typically 1/30. These previous studies did not report major change in lipid structure or 
phase behavior with inserted peptide. A different result was however reported for 
peptide bound from the aqueous phase. Our next study therefore focuses on the 
binding of non-treated amyloid peptide at high concentration from the aqueous phase 
to the membrane surface. The molar peptide-to-lipid ratio was 1/50 and the peptide 
VI. Amyloid peptide interaction with the lipid membrane  
 
78 
concentration of 800 M. As shown in Chapter IV, this high concentration and the 
absence of HFIP-pretreatment lead to large aggregates in buffer.  
Figure 17 summarizes the 31P-NMR experiments performed with POPC/d31-
POPG membranes in presence of AP(25-35), WAP(25-35) or AP(25-35)_I32W 
aggregates.  
Figure 17: 31P-NMR spectra of POPC/d31-POPG associated with (A) AP(25-35), (B) WAP(25-
35) and  (C) AP(25-35)_I32W at a peptide-to-lipid ratio of 1/50. The dry peptide powder was 
added to multilamellar lipid vesicles in 10 mM HEPES in deuterium-depleted water. The final 
peptide concentration was 800 M. The spectra were recorded from bottom to top at -10, -2, 0, 
2, 10, 20, 30 and 40°C.  
 
The spectra shown in Figure 17 are completely different from those obtained 
for the pure lipid mixture (see Figure 13A). Weak bilayer features are still observed for 
AP(25-35) or AP(25-35)_I32W (Figure 17A and 17B), however an intense isotropic 
line is superimposed on the bilayer spectra. The high-intensity shoulder characteristic 
of bilayer spectra observed at -15 ppm gradually shifts to -3 ppm upon temperature 
increase. In presence of WAP(25-35) aggregates at the membrane surface (Figure 
17B), no bilayer features can be observed but the signal at -3 ppm is also observed 
VI. Amyloid peptide interaction with the lipid membrane  
 
79 
upon temperature increase. An additional characteristic of these spectra is the 
decrease in intensity of the spectra with increasing temperature. Because of the 
superposition of different signals in each spectrum, the variations of with the 
temperature could not be determined. 
 
Figure 18: 2H-NMR spectra of POPC/d31-POPG associated with (A) AP(25-35), (B) WAP(25-35 
and (C) AP(25-35)_I32W at a peptide-to-lipid ratio of 1/50. The dry peptide powder was 
added to multilamellar lipid vesicles in 10 mM HEPES in deuterium-depleted water. The final 
peptide concentration was 800 M. The spectra were recorded from bottom to top at -10, -2, 0, 
2, 10, 20, 30 and 40°C. The inset in A shows the enlarged spectrum at -10°C. 
 
The results of the 2H-NMR experiments of the lipid membrane in presence of 
peptide aggregates are shown in Figure 18. The 2H-NMR spectra of the lipid membrane 
associated with amyloid model peptides are quite different from those observed with 
the inserted peptides (Figure 15).  
Bilayer features are still observed at low temperatures (see inset in Figure 18A) 
but an intense isotropic line hides the bilayer signal at higher temperatures. The 
quadrupole splittings can be determined at low temperature for AP(25-35) and 
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AP(25-35)_I32W and are found to be 35 kHz, similar to the  values measured with 
inserted peptides (Figure 16A). Above 4°C, the quadrupole splittings characteristic of a 
bilayer cannot be observed anymore. The abrupt change in the intensity of the central 
isotropic line indicates a phase transition of the peptide-associated bilayer at 4°C, 
which is similar to that of the vesicles containing the inserted amyloid model peptides. 
 
 
4. Discussion 
The data presented in this chapter provide new structural and thermodynamic 
input on the binding of model amyloid peptides to the lipid membrane. The CD 
experiments show the influence of Trp on the secondary structure of the bound 
peptides and prove that the lipid membrane favors the random-coil structure at low 
peptide concentration. Thermodynamic parameters of the peptide-to-lipid binding 
could be determined at pH 4.0. Eventually solid-state NMR study proved that the 
insertion of the model amyloid peptides increases the fluidity of the acyl chains while 
peptide adsorption on the membrane induces the formation of an isotropic lipid 
phase.  
 
a) Peptide structural change upon binding 
The CD spectra presented in this chapter provide evidence that the position of 
Trp influences the secondary structure of the bound amyloid model peptides. The 
experiments performed with HFIP-pretreated peptides indicate that AP(25-35)_I32W 
is more prone to -sheet formation upon lipid binding than AP(25-35) and WAP(25-
35) at both pH values (see Figure 12). -sheet formation in lipid-bound AP(25-
35)_I32W can be explained by the presence of Trp at the position 32 in the peptide 
sequence, since Trp is preferentially located close to the lipid carbonyl group28. This 
effect is complementary to the attraction of Lys28 for the lipid-water interface; the 
acyl chain of Lys is known to snorkel28, its hydrophobic part dives into the lipid 
membrane while the positively-charged terminal amino group remains at the lipid-
water interface. In contrast, Figure 12 shows that lipid binding at pH 7.4 and pH 4.0 
causes -structure decrease in AP(25-35) and WAP(25-35): the random-coil content 
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increases upon binding of the two peptides. It can be concluded that Trp24 does not 
favor -sheet formation upon binding to the lipid membrane. However the CD spectra 
presented in Figure 8B and 9B show a contribution of the aromatic side-chain of Trp24 
in the secondary structure19 of WAP(25-35) at both pH 4.0 and pH 7.4 that is not 
observed anymore after binding (see Figure 10B and 11B for comparison). Therefore 
Trp24 might also be involved in the change of secondary structure in WAP(25-35) 
upon binding to the lipid membrane.  
 
These CD experiments also provide elements to distinguish two roles of the 
lipid membrane on the secondary structure of AP(25-35) and WAP(25-35). In 1994, 
Terzi et al. studied AP(25-35) and AP(1-40)at a peptide concentration of 50 M. The 
authors showed that the -sheet content in these two peptides increases upon lipid 
addition9 at pH 5.0. Terzi et al. hypothesized that both peptides were unstructured at 
the first stages of lipid binding. The increase in -sheet in presence of lipid would occur 
either by peptide penetration in the hydrophobic part of the bilayer or by peptide 
aggregation at the membrane surface or by a penetration mechanism9. Chi et al. 
observed the crystalline ordering of AP(1-40) at 250 nM on the lipid surface upon 
association with DPPG with X-rays and neutron scattering, supporting the second 
hypothesis of Terzi29. Our work validates further the aggregation hypothesis of Terzi et 
al. The CD data shown in Figure 12 show that the lipid membrane tends to unstructure 
AP(25-35) and WAP(25-35) at a peptide concentration close to 20 M. Therefore 
our structural studies demonstrate that the lipid membrane unstructures low 
concentrated AP(25-35) and WAP(25-35) whereas it enhances -sheet formation at 
higher peptide concentration9. This indicates the presence of a critical step in peptide 
aggregation on the membrane that is function of amyloid peptide concentration, 
similar to the nucleus formation in solution30.    
 
b) Thermodynamic characterization of the binding mechanism 
At pH 4.0, the heat released during the binding of each amyloid model peptide 
with POPC/POPG SUVs (3:1, mol/mol) is weak and leads to constant values ofH0 at         
-1.38 and -3.04 kcal.mol-1 between 10 and 40°C for AP(25-35) and WAP(25-35), 
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respectively (see Table 1). This is in agreement with the previous work of Terzi et al. 9 
who measured H0 between -2 and -10 kcal.mol-1 (8.6 to 43 kJ.mol-1) for the binding of 
AP(25-35), AP(25-35)NH2 and AP(25-35NLe)NH2 to the same model membrane. 
The heats of reaction of AP(25-35)_I32W with the POPC/POPG SUVs (2:1, mol/mol) 
are much larger at pH 4.0  and increase with the temperature (see Table 2).  
The calorimetric study at pH 4.0 also shows that AP(25-35) and WAP(25-35) 
bind to the POPC/POPG (3:1, mol/mol) lipid membrane with low affinity with K0 = 11 
and 4 M-1, respectively (see Table 1). It is also the case for the binding of AP(25-
35)_I32W to POPC/POPG (2:1, mol/mol) lipid membrane with K0 ranging between 2 
and 6 M-1 (see Table 2). These values of K0 calculated with the binding model are 
similar to those calculated by Terzi9 for AP(25-35), AP(25-35)NH2 and AP(25-
35NLe)NH2, situated between 2 and 10 M
-1. The large difference shown in Figure 5 
between the intrinsic and the apparent binding constants points out the importance of 
electrostatic forces in the binding of AP(25-35) and WAP(25-35) to the lipid 
membrane. This confirms the experiment of Terzi9 who observed no more binding in 
presence of 100 mM NaCl.  
The binding of AP(25-35) to the lipid membrane at pH 4.0 is entropy-driven 
and peptide-to-lipid binding induces an increase in S0 (see Table 1) indicating an 
increase in disorder. This is mostly due to the release of water from the lipid 
membrane surface, but the loss of secondary structure of AP(25-35) upon binding 
observed by CD (see Figure 12) may also contribute. In contrast, the binding process of 
WAP(25-35) to POPC/POPG SUVs (3:1, mol/mol) at pH 4.0 is enthalpy-driven, similar 
to the binding of AP(25-35)_I32W to POPC/POPG SUVs (2:1, mol/mol) at the same pH 
value (see Table 1 and 2).  
 
At pH 7.4, AP(25-35)_I32W binds quickly to the POPC/POPG (2:1, mol/mol) 
membrane and releases little heat (see H0 values in Table 3). In contrast to the 
experiment with AP(25-35)_I32W at pH 4.0, but similar to the binding of AP(25-35) 
at pH 4.0, the binding of AP(25-35)_I32W is entropy-driven. S0 is large and positive; 
TS0 varies from 4.0 to 4.8 kcal.mol-1 (16.7 to 20.1 kJ.mol-1) over the temperature 
range studied (from 12 to 25°C). The binding is characterized by a heat capacity change 
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Cp = 38 cal.mol-1.K-1. Cp is the most reliable parameter to give information on the 
driving forces of a binding reaction. Indeed the simple comparison of the enthalpy and 
entropy values is insufficient to define the binding mechanism, as was shown with the 
description of the nonclassical hydrophobic effect13,31. Cp is associated with the 
dehydration of nonpolar surfaces32. In the case of a negative Cp value, the binding 
process is mainly due to hydrophobic contributions33. The positive value calculated 
from our calorimetric titrations is unexpected, since the transfer of a hydrophobic 
group, i.e. the amyloid model peptide, from the aqueous phase to the hydrophobic 
lipid bilayer is characterized by a negative Cp34. This slightly positive value could be 
due to the increased exposure of hydrophobic areas to the aqueous buffer34. 
Eventually the free energy is more favorable than at pH 4.0 with G0 = -4.2 kcal.mol-1 
(see Table 3). 
 
c) Enthalpy-entropy compensation  
The free energy of binding for all three peptides is stable around -3.3 kcal.mol-1 
at pH 4.0 and -5.3 kcal.mol-1 at pH 7.4 (-13.8 and -22.2 kJ.mol-1), indicating an enthalpy-
entropy compensation mechanism. The compensation mechanism is represented by a 
linear correlation between the enthalpy H0 and the entropy of reaction TS0 
according to Equation (7)35: 
0
0
00 STHST 	   (7) 
Table 5: Parameters of the equation TS0= H0 + TS00 for the binding of AP(25-35), 
WAP(25-35) and AP(25-35)_I32W. The correlation is found for all binding conditions studied. 
The slope , the intercept TS00 and the correlation coefficient R2 are summarized.  
 
  
/ 
TS00
 
(kcal/mol) 
R2 
/ 
pH 4.0 
AP(25-35) 3.55 7.24 0.98 
WAP(25-35) 1.00 3.24 0.99 
AP(25-35)_I32W (2:1) 0.92 2.49 0.99 
pH 7.4 AP(25-35)_I32W (2:1) 1.24 5.55 0.99 
 
The slope  (see Table 5) indicates the extent to which enthalpy contributes to the 
free energy of binding, that is to say to the system stability35. The intercept TS00 
theoretically represents the system stability when the enthalpy is zero. In the absence 
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of enthalpic contribution, the entropy leads to favorable equilibrium, with TS00
between 2.5 and 7.2 kcal.mol-1 (10.5 to 30.1 kJ.mol-1).  
 
d) Structure of the amyloid model peptides associated with the lipid membrane
The combination of the thermodynamic data with peptide secondary structure 
gives indications on the geometry of each peptide on the lipid membrane. Figure 19 
shows a speculative model based on the structure of AP(25-35) in HFIP/water (20:80, 
v/v)36, for AP(25-35) and WAP(25-35) in Figure 19A and 19B, respectively. As the 
crystallization of fibril-forming peptides is difficult, no crystal structure of -sheet 
AP(1-40) or any of his model peptides are available. Therefore the -sheet structure 
of AP(25-35)_I32W in Figure 19C is based on the crystal structure of -synuclein37. 
 
Figure 19: Representation of a possible geometry of (A) AP(25-35), (B) WAP(25-35) and (C) 
AP(25-35)_I32W in their bound state. The lipid membrane surface would be at the bottom of 
the peptides in order to interact with the side chain of Lys28 and Trp32 or Trp24. The original 
crystal structures36,37 were modified with PyMol. The side-chains of the amino-acids are 
represented in the most favorable conformation that matches our ITC and CD data. The 
snorkeling of the Lys acyl chain could not be represented with PyMol.  
 
The binding of AP(25-35), WAP(25-35) and AP(25-35)_I32W is controlled by 
the electrostatic attraction of Lys28 to the negatively-charged POPG headgroup. Bound 
AP(25-35) is unstructured; the only knowledge regarding peptide geometry is 
therefore the snorkeling of the acyl side-chain of Lys28 in the lipid membrane38 (see 
Figure 19A).  
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The additional Trp in the sequence of WAP(25-35) and AP(25-35)_I32W also 
influences the binding mechanism as the side-chain of this residue can insert into the 
membrane28. The peptide chain of WAP(25-35) could be aligned partially parallel to 
the lipid membrane surface to allow the insertion of the indole group of Trp24 and the 
snorkeling38 of the side-chain of Lys28 inserted into the lipid membrane surface (see 
Figure 19B).  
Binding to the lipid membrane induces -sheet of AP(25-35)_I32W.  The side-
chains of Lys28 snorkels38 and that of Trp32 inserts into the apolar environment of the 
lipid membrane. A possible structure is therefore shown in Figure 19C. The -sheet 
formed by AP(25-35)_I32W on the surface could include a three-amino-acid long 
loop, from Gly29 to Ile31.  
 
e) Structure of the lipid membrane upon peptide insertion or binding 
The insertion of the three amyloid model peptides into the membrane leaves 
the lipid bilayer intact, similar to AP(1-40)8. In effect, the large quadrupole splitting of            
? 27 kHz and the chemical shielding anisotropy of -50 ppm at high temperature are 
characteristic values for a lipid bilayer39-41 and are similar to the results found for pure 
POPC/d31-POPG lipid bilayers (see Figure 14 and 16). The lipid membranes with 
inserted model peptides have melting transitions close to those of the pure lipid 
membrane. The d31-POPG acyl chains melt at Tm = 4°C (see Figure 16A), slightly above 
the pure lipid membrane (Tm = -3°C). In contrast, the lipid headgroups suggest an even 
higher transition temperature of 2 to 6°C (see Figure 14). 
Below Tm, the lipid chains become more rigid and the quadrupole splittings are 
small (see Figure 16). Also the quadrupole splittings of the lipid membrane with the 
model peptides, Q(CD2)pep and Q(CD3)pep, are smaller than the splittings of the 
pure lipid membrane, Q(CD2)lipid, in the gel phase: the insertion of peptide in the lipid 
membrane stiffens further the acyl chains. Above Tm, Q(CD3)pep and Q(CD2)pep 
become smaller with the increasing temperature in the presence of amyloid model 
peptides whereas both splittings remain constant in the lipid membrane without 
peptide. Q(CD2)pep is 10% smaller than Q(CD2)lipid at 10°C and becomes 25% smaller 
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at 40°C in presence of peptides. The difference is even larger for Q(CD3)pep: it is 19% 
smaller than Q(CD3)lipid at 10°C and 40% smaller at 40°C. This observation indicates a 
higher mobility in the liquid-crystalline phase of the lipid chains in presence of amyloid 
peptides. These variations of quadrupole splittings are similar for all three peptides 
and to our knowledge, have never been observed in the past. In effect the insertion of 
cytochrome c oxidase in a d9,10-1,2-dioleoyl-sn-glycero-3-phosphocholin membrane did 
not induce any major change in the quadrupole splittings42 measured with 2H-NMR. 
Similarly the insertion of a cationic amphiphilic peptide in DMPC membranes with 
perdeuterated acyl chains did not lead to any perturbation of the quadrupole 
splittings43. 
The chemical shielding anisotropy  of the lipid membrane in presence of 
AP(25-35) or WAP(25-35) is smaller than lip of the pure lipid membrane both in 
the gel phase and in the liquid-crystalline phase (see Figure 14). In presence of AP(25-
35)_I32W,  is larger than lip below Tm but becomes smaller above Tm. Upon 
temperature increase the difference between  of the lipid membrane in presence of 
any of the three amyloid model peptides and lip decreases;  is 15% smaller than 
lip at 6°C and only 10% smaller at 12°C. The insertion of the amyloid model peptides 
into the lipid membrane slightly increases the mobility of the lipid headgroups, 
however this mobility decreases with the increasing temperature, in contrast to the 
acyl chains. Similarly to our results, Bokvist et al.26 showed a decrease in the motions 
of the lipid headgroups of membranes with AP(1-40) inserted.  
 
The presence of amyloid peptide aggregates on the membrane surface leads to 
important structural modifications of both the lipid headgroups and acyl chains. 
Although the bilayer structure is present in both 2H- and 31P-NMR spectra (see Figure 
16 and 17), an additional isotropic peak is observed after association of aggregates of 
AP(25-35), WAP(25-35) or AP(25-35)_I32W with the lipid membrane. This isotropic 
phase is favored by high temperatures and the bilayer features cannot be observed 
anymore. Additional DSC experiments in crucible would allow the observation of 
distinct phase transitions of the POPC/POPG membrane in presence of amyloid 
peptide aggregates at the low temperature range required.  
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A modification of the lipid membrane structure upon amyloid peptide 
association was already reported in the literature. A change of the structure and 
dynamics of a DMPC/DMPS lipid bilayer upon AP(25-35) association was shown by 
Buchsteiner et al44. The authors used neutron diffraction to prove the disordering of 
the lipid and the increase in lipid mobility and lateral diffusion. Other evidence from 
membrane structural changes was reported by Demuro et al. who showed the ability 
of AP(1-42) to release calcein from human neuroblastoma cell45. The DSC study 
performed by Del Mar et al. on DMPG vesicles associated with AP(1-40) at pH 7.4, 
showed an additional shoulder in the calorimetric profile compared to DMPG alone46, 
and was taken as evidence for the formation of a new lipid phase. 
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VII. Appendix: Gouy-Chapman theory 
 
 
 
As was detailed in the Chapter VI (see p.60), Boltzman’s law describes the 
electrostatic equilibrium between the peptide concentration close to the membrane, 
cM, with the concentration of free peptide in the bulk solution, cf, considering the 
surface potential Ψ0  at the membrane surface. 
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The membrane potential Ψ0 cannot be measured directly. However it is related 
to the membrane surface charge density σ which, in turn, can be expressed as a 
function of the extent of binding Xb. The Gouy-Chapman theory1,2 provides the relation 
between Ψ0 and σ according to: 
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with zi the signed valency of the ith species in the bulk phase and ci its concentration. ε0 
is the permittivity of the free space, εr the dielectric constant of the aqueous phase3,4, 
RT the thermal energy and F0 the Faraday constant.  
 
The membrane surface charge density can be independently determined from 
the extent of binding with the relation derived by Seelig and Beschiaschvili5: 
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AL is the surface area of lipid (AL = 68 Å for POPC and POPG6,7), Apep is the 
peptide surface area and can be estimated with surface activity measurements8, zpep is 
the peptide effective charge, XNa the mole fraction of bound sodium anions, XoL the 
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mole fraction of charged lipids, Xb the mole fraction of bound peptide. As Apep is 
between 50 and 150 Å for most peptides, the correction term for peptide penetration 
into the membrane Apep/AL Xb is small compared to unity and can been neglected for 
molecules which do not penetrate into the membrane. 
 
The above relationships (Equations (5), (8) and (9)) together with the law of 
mass conservation make it possible to calculate the surface potential Ψ0 and the 
peptide concentration at the membrane surface cM for each value of bound peptide 
Xb. These equations together with the ones described in the Chapter VI will be used to 
find the best fit to the data obtained from ITC measurement.  
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VIII. Appendix: solid-state NMR 
 
 
 
Solid-state nuclear magnetic resonance (ssNMR) investigates the anisotropic 
motions of a nucleus in a magnetic field and provides information on the nucleus 
environment. Phosphorus, deuterium and carbon NMR are the most common 
methods in lipid membrane studies. In phosphorus and carbon ssNMR, anisotropic 
chemical shift and heteronuclear dipolar coupling give rise to line broadening, whereas 
in deuterium ssNMR anisotropic motions are easily detected. The principle of the 
ssNMR techniques used in this work, 31P- and 2H-NMR, are briefly detailed thereafter. 
 
 
1. 31P-NMR 
The natural abundance of 31P is 100%, and phosphorus NMR is a conventional 
method to study the orientation and structure of the phospholipid headgroups. In the 
case of a single crystal, the phosphate groups have a unique orientation with respect 
to the crystal axes. As all phosphates are aligned in the same direction, they give rise to 
the same sharp phosphorus resonance1. Due to the anisotropy of the electron density 
around the phosphorus atom, the chemical shielding of the applied magnetic field 
depends on the orientation of the phosphorus nuclei. Therefore upon rotation of the 
crystal in the magnetic field, these resonances will shift their position with respect to a 
fixed reference signal. The complete rotation pattern of a single crystal leads to the 
determination of the principal components (11, 22, 33) of the chemical shielding 
tensor1 (see Figure 1). The orientation of the chemical shielding tensor determined 
with phosphoethanolamine crystal is usually taken as a reference for the other 
phospholipids.  
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Figure 1: Orientation of the chemical shielding tensor in the molecular frame of the phosphate 
segment. O1 connects the phosphate group with the backbone and O2 with the head group 
residue. O3 and O4 represent the nonesterified oxygens. Reproduced from 
1. 
 
In the case of an oriented bilayer, the phosphate groups rotate around the 
bilayer normal, leading to a partial averaging of the shielding tensor. This averaged 
tensor is axially symmetric and has two principal components, ?and??(see Figure 
2).  
In the case of a powder type sample, each microdomain has a different 
orientation with respect to the applied magnetic field. If averaged over time, each of 
these orientations has a defined probability. The superposition of the phosphorus 
resonances combined with their probability produces the observable spectrum (see 
Figure 2).  
 
Figure 2:  31P-NMR spectra of bilayers of dimyristoyl-phosphatidylglycerol (DMPG) at 30°C.The 
chemical shielding anisotropy is directly measured from the distance between the low- and 
high-field shoulders. 

is measured in the 31P-NMR spectrum as the distance between the low- and 
the high-field shoulder (see Figure 2), ??. It results from the averaging of the 
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chemical shielding tensor and is a measure of the orientation and average fluctuations 
of the phosphate headgroup. Unsonicated phospholipid bilayers in a magnetic field 
typically have a 31P NMR powder chemical shielding anisotropy of 50 ppm. 
 
 
 
2. 2H-NMR 
Deuterium NMR observes the fluctuations of the labeled phospholipid chains 
via deuteron resonance frequencies with respect to the applied magnetic field. The 
deuterium spectrum consists of an isotropic line in the case of rapid isotropic motions. 
In the case of anisotropic motions each deuteron gives rise to a doublet due to the 
quadrupole moment of the deuterium nucleus.  
 
Figure 3: Dimyristoylphosphatidyglycerol molecule in a magnetic field B0. The C-D bond 
orientation is defined with the angle with respect to the bilayer normal.  
 
The doublet spacing, also named quadrupole splitting Q, depends on the 
degree of anisotropy of the powder-type sample and on the orientation of the C-D 
bond vector according to2: 
CDQ Sh
qQe2
4
3
	   
with e2qQ/h the quadrupole coupling constant and SCD the order parameter of the C-D 
bond. This latter is expressed as function of the angle between the bilayer normal and 
the C-D bond (see Figure 3) as follows: 
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As an example3, a bilayer in the gel phase has an order parameter SCD = -0.4. The C-D 
bond order parameter is correlated to the molecular order parameter with the 
relation: 
CDmol SS 2  
 
The quadrupole splitting can be directly measured on the 2H-NMR spectrum, as 
shown in Figure 4. The spectrum observed is the superposition of quadrupole splittings 
of each deuteron present in the lipid chain.
 
Figure 4: 2H-NMR spectra of POPC/d31-POPG bilayer. The quadrupole splittings represented in 
red originate from the terminal deuterons on the lipid chain (Q(CD3)) or from the closest 
deuterons to the phosphate headgroup (Q(CD2)).  
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IX. Appendix: ITC titrations 
 
 
 
The thermodynamic parameters, given in Table 1, 2, 3 and 4 of the Chapter VI, result 
from the fitting of the experimental data with the surface partitioning model combined with 
the Gouy-Chapman theory. All titrations are shown in the following section.  
The title of each subsection indicates the peptide titrated, the pH and the molar 
POPC-to-POPG ratio. The peptides titrated were AP(25-35), WAP(25-35) or AP(25-
35)_I32W. The titrations were performed in 10 mM HEPES buffer at pH 7.4 or in 10 mM 
AcONa buffer at pH 4.0. The lipid system was POPC/POPG either at a ratio of 3:1 or 2:1, 
mol/mol. The SUVs were prepared as described in Chapter VI (Materials and Methods). 
Each titration shows the same information. The upper figure represents the heat 
flow. The lower figure shows the cumulative heat of reaction as a function of the lipid-to-
peptide molar ratio. The values on the right-hand side are the integrated heats of reaction in 
cal for each lipid injection. In the lower figure, additional data are given: the peptide 
concentration cpep in the sample cell, the lipid concentration clip in the syringe, the 
temperature T of the cells during the titration, the values of the enthalpy H0, free energy 
G0, entropy S0 and intrinsic binding constant K0 of the reaction. The last indication in italic 
is the name of the file where the raw data are stored. 
The injection volume of all titrations shown is 10 l.  
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1. WbAP(25-35) titrations with POPC/POPG SUVs (3:1) at pH 4.0 
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2. AP(25-35) titrations with POPC/POPG SUVs (3:1) at pH 4.0 
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3. AP(25-35)_I32W titrations with POPC/POPG SUVs (3:1) at pH 4.0 
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4. AP(25-35)_I32W titrations with POPC/POPG SUVs (3:1)  at pH 7.4 
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5. AP(25-35)_I32W titrations with POPC/POPG SUVs (2:1) at pH 4.0 
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6. AP(25-35)_I32W titrations with POPC/POPG SUVs (2:1) at pH 7.4 
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1. Abstract 
The synthetic lipid 1,2-dimyristoyl-sn-3-phosphoglycerol (DMPG), when 
dispersed in water/NaCl exhibits a complex phase behavior caused by its almost 
unlimited swelling in excess water. Using deuterium (2H)- and phosphorus (31P)-NMR 
we have studied the molecular properties of DMPG/water/NaCl dispersions as a 
function of lipid and NaCl concentration. We have measured the order profile of the 
hydrophobic part of the lipid bilayer with deuterated DMPG while the orientation of 
the phosphoglycerol headgroup was deduced from the 31P-NMR chemical shielding 
anisotropy. At temperatures >30 °C we observe well-resolved 2H- and 31P-NMR spectra 
not much different from other liquid crystalline bilayers. From the order profiles it is 
possible to deduce the average length of the flexible fatty acyl chain. Unusual spectra 
are obtained in the temperature interval of 20 °C to 25 °C, indicating one or several 
phase transitions. The most dramatic changes are seen at low lipid concentration and 
low ionic strength. Under these conditions and at 25 °C the phosphoglycerol 
headgroup rotates into the hydrocarbon layer and the hydrocarbon chains show larger 
flexing motions than at higher temperatures. The orientation of the phosphoglycerol 
headgroup depends on the bilayer surface charge and correlates with the degree of 
dissociation of DMPG-Na+. The larger the negative surface charge the more rotates the 
headgroup towards the non-polar region.   
 
 
2. Introduction 
Phosphatidylglycerol (PG) is one of the predominant biological lipids and has 
been found to occur in higher plants, algae, bacteria and, to a lesser extent, in animal 
tissue. PG is negatively charged at physiological pH with an apparent pK of the 
phosphate group of pK = 2.9 - 5.5.1,2 2H- and 31P- NMR as well as neutron diffraction 
have been used to deduce the conformation and dynamics of PG bilayers. 3-6 The 
phosphoglycerol headgroup was found to be oriented at about 30° to the membrane 
surface making the negatively charged phosphate group easily accessible to cations, 
present in the bulk aqueous phase. The influence of Ca2+ on membranes composed of 
synthetic 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) and natural PG 
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isolated from E.coli, either in pure form or mixed with neutral 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC), was also investigated with 2H- and 31P-NMR.7 The 
binding of Ca2+ leads to a considerable increase in the transition temperature of the 
gel-to-liquid crystal phase transition. The conformation of the phospholipid 
headgroups changes upon Ca2+ binding and NMR can be used to deduce the binding 
isotherm. Nevertheless, a headgroup orientation essentially parallel to the membrane 
surface is maintained.   
Among the synthetic phosphatidylglycerols 1,2-dimyristoyl-sn-glycero-3-
phospo-rac-glycerol (DMPG) has received particular attention because of its unusual 
phase properties. It appears to form single bilayers when dissolved in water at low lipid 
and low salt concentration.8 DMPG-Na+ has been claimed to dissolve as a monomer 
with a solubility coefficient of ~4.6 x 10-5 M at 25 °C (9, figure 2). Multilamellar bilayer 
dispersions of DMPG-Na+ show an almost unlimited uptake of water due to 
electrostatic repulsion of juxtaposed bilayers.10 In early studies of DMPG-Na+ 
differential scanning calorimetry (DSC) revealed a gel-to-liquid crystal transition at 
24 °C with a transition enthalpy of ΔH = 6.8 – 7.0 kcal/mol.11,12 Subsequently, an 
additional pre-transition at 13 – 15 °C with a smaller enthalpy of ΔH ~ 0.6 kcal/mol was 
detected.13-20 The molecular basis of the pre-transition is a realignment of the 
extended hydrocarbon chains in gel-state. A pre-transition and a gel-to-liquid crystal 
main transition are also typical for neutral phosphatidyl cholines.21,22 For example, 
bilayers of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) in excess water exhibit 
a pre-transition and a main transition with very similar parameters as those of DMPG-
Na+ in 0.1 M NaCl. However, in addition to pretransition and main transition DMPG-
Na+ displays an even more complex phase behavior at low salt content 8,23,24 which was 
described as "the solution phase containing monomer or micelle, the two bilayer 
phases (gel and liquid crystal) and the three morphologically distinct bilayer states 
[jelly, unilamellar vesicles (LUV) and multilamellar vesicle (MLV)]".8 Most remarkable 
and different from other phospholipids is the jelly-like state of DMPG-Na+ at low lipid 
and low salt concentration which has a completely transparent structure of high 
viscosity.14 Freeze-fracture studies of DMPG in distilled water showed particles with 
morphologies different from bilayer vesicles. It was concluded that "the lipid appears 
visually to 'dissolve' in distilled water".24  
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These initial observations stimulated a series of further investigations to 
characterize the phase diagram of DMPG-Na+ in detail and to elucidate the lipid 
packing in the different phases. DMPG-Na+ dispersions require careful attention to the 
exact quantitative composition of the system such as lipid concentration, the presence 
of salt/buffer, pH and temperature.25,26 This is quite different compared to zwitterionic 
lipids where a small excess of water is usually sufficient to establish unambiguous 
physical conditions. Of particular interest is DMPG-Na+ at low lipid concentration and 
low ionic strength. The molecular picture associated with the phase transition region is 
that of "uncorrelated bilayers in which in-plane correlated cavities/pores open on the 
membrane surface, giving rise to mesoscopic correlation".19,27 This model is supported 
by fluorescence measurements suggesting "open (tattered)" bilayer sheets in the 
transition region.28  
The purpose of the present study is to investigate the unusual phase behavior 
of DMPG-Na+ dispersions with deuterium (2H) and phosphorus (31P) NMR. These 
methods allow a clear distinction between bilayer and non-bilayer phases.29,30 Four 
different regions will be considered, characterized either by high or low lipid 
concentration and both measured at either high or low NaCl concentration.  
 
 
3. Methods 
Solid-State NMR. Solid state NMR experiments were performed on a Bruker 
Avance 400MHz spectrometer (Bruker AXS, Karlsruhe, Germany).  
Solid-state 31P-NMR spectra were recorded at 162 MHz using a pulse-acquire 
sequence with broadband proton decoupling (WALTZ-16) and a recycle delay of 6s. 
The excitation pulse length was 3s and 1000 FIDs were accumulated. The chemical 
shielding anisotropy, , was determined by a simulation of the spectra.30 
Solid state 2H-NMR experiments were recorded at 61 MHz using the 
quadrupole echo technique. The excitation pulse had a length of 5.5 s. 8 K FIDs were 
accumulated with a recycle delay of 250 ms.  
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Differential Scanning Calorimetry. A Microcal VP-DSC microcalorimeter with a 
scan rate of 45 °C/h and a cell volume of 0.5 mL was used for the low lipid content 
samples (~ 20 mg/mL = 27 mmol/kg lipid, using a molecular weight of DMPG-
Na+ = 688 g/mol plus 3 H2O). The samples were scanned in the range of 10 to 60 °C. As 
a control, pure buffer was measured as baseline. The Microcal Origin software was 
used for data evaluation. Each DSC measurement was reproduced at least twice. 
 
Mass Spectrometry. Thin-Layer Chromatography. After the NMR experiments 
the stability of the lipid was checked with mass spectrometry and thin layer 
chromatography. The mass of the lipid at low ionic strength was assessed by Voyager-
DE Pro mass spectrometer (Applied Biosystems; Foster City, U.S.A.). The lipid was run 
on a TLC plate (Fluka) in a dichloromethane/methanol/water mixture (70/26/4) and 
was exposed to iodine vapor. In both assays no differences to fresh DMPG were 
detected. 
 
Sample preparation. 1,2-Dimyristoyl-sn-glycero-3-phospho-rac-glycerol (DMPG, 
molecular weight 688.4 g.mol-1) and 1,2-dimyristoyl-d54-sn-glycero-3-phospho-rac-
glycerol in chloroform (d54-DMPG, molecular weight of 743.2 g.mol
-1) were purchased 
from Avanti Polar Lipids (Alabaster, USA).  
Two types of buffers were used. Low ionic strength buffer composed of 10 mM 
Hepes, pH 7.4, 2 mM NaCl, or high ionic strength buffer 10 mM Hepes, 100 mM NaCl, 
pH 7.4. For deuterated lipid samples the buffer was made with deuterium-depleted 
water.  
 
Non-deuterated NMR samples. 50 mg of DMPG as a powder was dispersed in 
250 μL of buffer to produce the high lipid content sample molality (270 mmol/kg). 13.7 
mg of DMPG as a powder was dispersed in 400 μL of buffer to produce the low lipid 
content sample (50 mmol/kg). Multilamellar vesicles were formed by vortexing the 
dispersion. 10 freeze-thaw cycles were made to obtain homogeneous multilamellar 
vesicles. Each freeze-thaw cycle consisted of three steps: freezing the sample to -80 °C, 
warming it up to room temperature and vortexing it. 
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Deuterated NMR sample. 19 mg of DMPG as a powder and 6 mg of d54-DMPG 
in chloroform were dried under a stream of nitrogen and then under high vacuum 
overnight. The film was dispersed in 250 μL of buffer to produce the high lipid content 
sample (143 mmol/kg). 10.3 mg of DMPG as a powder and 3.5 mg of d54-DMPG in 
chloroform were dried under a stream of nitrogen and then under high vacuum 
overnight. The film was dispersed in 400 μL of buffer to produce the low lipid content 
sample (50 mmol/kg DMPG). Multilamellar vesicles were formed by vortexing the 
dispersion. 10 freeze-thaw cycles were made to obtain homogeneous multilamellar 
vesicles.  
 
 
4. Results 
DMPG Suspensions at High Lipid Content. In a first series of experiments DMPG-
Na+ was dispersed at a lipid molality of 270 mmol/kg in 100 mM NaCl, 10 mM Hepes, 
pH 7.4. 31P-NMR spectra were recorded in the range of 15 °C to 50 °C and are shown in 
figure 1 for temperatures above (1A) and below (1B) the phase transition. The spectra 
are characteristic of multilamellar lipid bilayers. The anisotropic motion of the 
phosphate group can be quantitated by the chemical shielding anisotropy, , 
measured as the distance between the low- and high-field shoulders of the 31P-NMR 
spectrum 31 (indicated by arrows in 1B).  
Figure 1 compares the experimental spectra (black lines) with theoretical 
simulations (red lines). At 20 °C (fig. 1B), that is, for the viscous gel-phase the 
agreement between theory and experiment is excellent. The chemical shielding 
anisotropy is Δσ = -45.5 ppm and the shape of the spectrum corresponds to a random 
distribution of bilayers ("powder-type spectrum"). Above the phase transition 
temperature (25 °C, fig 1A) the experimental spectrum has excess intensity at the high-
field shoulder, suggesting a magnetically induced alignment for about 20% of the 
bilayers such that the planes of the oriented domains are parallel to the B0 field.32 As 
all bilayers carry a negative surface charge the electrostatic repulsion between 
adjacent bilayers is strong, leading to an increase in the intermembrane distance. 
Consequently, more water can be imbibed between juxtaposed bilayers facilitating the 
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motion and reorientation of the bilayers in a strong magnetic field. Magnetic 
alignment has first been reported for Eschericia coli lipids containing about 20 % PG 
and for a mixture of synthetic phosphatidylethanolamine and phosphatidylglycerol, 
both containing cis-unsaturated fatty acids.32 It has also been observed by 2H-and 
31P-NMR for phospholipid bilayers consisting of a 40:60 mixture of N-
palmitoylsphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphocholine.33 The 
present data represent the first observation of magnetic alignment for a phospholipid 
with 2 saturated fatty acyl chains and a phosphoglycerol headgroup. Magnetic 
alignment is additional evidence for a lamellar structure as other structures such as 
micelles or cubic phases cannot be magnetically ordered for symmetry reasons.  
 
 
 
Figure 1: 31P-NMR spectra of DMPG-Na+ bilayers at high lipid and high salt concentrations 
DMPG-Na+ at a molality of 270 mmol/kg was dispersed in buffer composed of 100 mM NaCl, 10 
mM Hepes, pH 7.4 (A) 25 °C, (B) 20 °C. Black line: experimental spectrum; red line: simulation 
according to 29. 
 
The temperature dependence of the chemical shielding anisotropy, Δσ, is 
shown in figure 2A (♦) and reveals a phase transition at 23 °C. Above this temperature 
the bilayer is in the liquid-crystalline state and the chemical shielding anisotropy is 
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almost constant with  = -37 ppm at 23 °C and -36 ppm at 50 °C. Below Tc = 23 °C the 
bilayer is in a gel-like state and  decreases rapidly to -50 ppm. In parallel, the rate of 
reorientation of the phospholipid headgroup slows down.  
 
Figure 2: 31P- and 2H-NMR anisotropy parameters of DMPG-Na+ bilayers at a lipid molality of 
270 mmol/kg 
(♦) 100 mM NaCl, 10 mM Hepes, pH 7.4. (◊) 2 mM NaCl, 10 mM Hepes, pH 7.4. (A) 31P-NMR 
chemical shielding anisotropy Δσ; (B) quadrupole splitting, ΔνQ, of the terminal -CD3 groups. At 
low ionic strength 2 separate quadrupole splittings are observed in the transition region, (C) 
quadrupole splitting, ΔνQ, of -CD2-groups located close to the lipid-water interface, giving rise 
to the maximum splitting.  
 
A different picture was obtained for 31P-NMR spectra measured at the same 
high lipid molality of 270 mmol/kg but at low ionic strength (2 mM NaCl, 10 mM 
Hepes, pH 7.4). Figure 3A compares 31P- NMR spectra in the range of 19 °C to 23 °C.  
Two features are notable. (i) At 20 °C the spectrum is a superposition of 2 
spectra indicating the coexistence of two bilayer phases. This appears to be an 
equilibrium situation as exactly the same spectrum is obtained after 5 hrs of 
equilibration at this temperature. (ii) The spectra at 21 °C and higher temperatures are 
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consistent with a single phase but are again characterized by an increased intensity of 
the high-field shoulder. Spectral simulations reveal that about 20% of the total lipid 
material is magnetically aligned.  
The temperature dependence of the chemical shielding anisotropy, Δ, at low 
ionic strength is included in figure 2A (). Compared to spectra at 100 mM NaCl the 
transition region is broader and extends from 20 °C to 24 °C. Unexpectedly, the size of 
Δ goes through a distinct minimum in this temperature interval indicating an unusual 
change in orientation of the phosphoglycerol headgroup (cf. Discussion).  
 
Figure 3: 31P- and 2H-NMR spectra of DMPG -Na+ lipid bilayers at high lipid content but low 
ionic strength buffer 
(A) 31P-NMR 50 mg of DMPG-Na+ was dispersed in 250 µL of low ionic strength buffer (10 mM 
Hepes, 2 mM NaCl, pH 7.4) (lipid molality  270 mmol/kg). (B) 2H-NMR 6 mg perdeuterated of 
d54-DMPG-Na
+ and 19 mg of DMPG were dispersed in 100 µL of the same buffer as in (A) (lipid 
molality 340 mmol/kg).  
 
The hydrophobic part of the bilayer was monitored with 2H-NMR using DMPG-
Na+ with 2 perdeuterated myristic acid chains and mixed with non-deuterated DMPG-
Na+ at a 1:3 (deuterated/non-deuterated) molar ratio. 2H-NMR spectra of lipid bilayers 
at low ionic strength are shown in figure 3B providing independent evidence for the 
co-existence of two different bilayer phases in the transition region. The spectra arise 
from a superposition of the time-averaged quadrupole splittings of all deuterated 
chain segments. The size of the quadrupole splitting varies along the chain. An 
unambiguous assignment can be made for the high-intensity, innermost splitting which 
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comes from the terminal -CD3 groups of both chains. Figure 3B reveals two CD3- 
splittings in the transition region with separations of nQ ~ 3 kHz and 6.5 kHz. As the 
temperature is raised from 22 °C to 24 °C, the intensity of the 3 kHz splitting increases 
at the expense of the 6.5 kHz splitting, confirming the co-existence of 2 bilayer phases. 
Figure 2B summarizes the temperature dependence of nQ(-CD3) for both high and low 
NaCl concentrations. Very similar quadrupole splitting are measured for DMPG 
membranes suspended in 100 mM NaCl (♦) or 2 mM NaCl (). An increase in the 
quadrupole splitting occurs when the temperature is lowered below 24 °C. The gel-to-
liquid phase transition of the perdeuterated DMPG-Na+ is about 1 °C higher than that 
of the non-deuterated lipid because of stronger van-der-Waals interactions. Figure 2B 
shows 2 splittings for the CD3-groups in the phase transition region.  
The ordering of the hydrocarbon chains can be deduced from the edges of the 
deuterium NMR spectra (fig. 3B). The quadrupole splittings range between 19 kHz at 
55 °C and 32 kHz at 20 °C. They reflect the anisotropic motion of those -CD2- segments, 
which are located near the lipid-water interface.33 Figure 2C summarizes the 
temperature dependence of the nQ (-CD2-). Again, very similar quadrupole splittings 
are observed at 100 mM NaCl (♦) and 2 mM NaCl (). The increase in nQ(-CD2-) at 
about 24 °C reflects the phase transition region. However, even below the phase 
transition the fatty acyl chains are not extended in the all-trans conformation as a 
much larger quadrupole splittings of ~60 kHz would be expected. The experimental 
observations yield only ~32 kHz, indicating considerable chain flexing motions.  
We observed thixotropy for samples which contained perdeuterated DMPG at 
high lipid concentration and high ionic strength. Freshly prepared samples showed 
typical bilayer 2H- and 31P-NMR spectra up to the highest temperature (50 °C). When 
NMR-sample tube was then taken out of the NMR spectrometer and was slightly 
shaken it became completely transparent. Re-insertion into the NMR spectrometer 
produced only isotropic lines, indicating an increased fluidity. Bilayer-type spectra 
returned only after months of storage at low temperature.  
 
DMPG Suspensions at Low Lipid Content. The thermodynamic phase transitions 
of DMPG-Na+ suspensions at low lipid content (molality ≤ 50 mmol/kg) and high salt 
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concentration have been investigated with DSC by several groups.15,16,19,25,28 For 
samples dispersed at ≥ 100 mM NaCl the DSC scans reveal a pre-transition at 13-14 °C 
and a gel-to-liquid crystal transition at ~23 °C as confirmed in figure 4A for a sample 
used in the present NMR experiment.  
 
Figure 4: DSC thermograms of DMPG-Na+ suspensions 
(A) Low lipid concentrations, high ionic strength. 20.3 mg DMPG suspended in 1 mL at 100 mM 
NaCl, 10 mM Hepes, pH 7.4 (lipid molality 27.4 mmol/kg). The scan rate was 45 °C/h. 35 scans 
were performed yielding identical thermograms. (B) Low lipid concentration, low ionic strength. 
19.8 mg DMPG dispersed in 1 mL buffer (2 mM NaCl, 10 mM Hepes, pH 7.4) (lipid molality 
27 mmol/kg). 49 scans were obtained over a period of 5 days.  
 
The 2H- and 31P-NMR spectra of such bilayers are not shown as they are similar 
to those in figure 1. However, their NMR anisotropy parameters are reported in figure 
5. Most obvious is the change in the 31P-NMR chemical shielding anisotropy (5A,) 
from -39 ppm at 22 °C to -48 ppm at 20 °C. The phase transition occurs at the same 
temperature as found for the high lipid and high salt concentration (5A, ♦). The same 
phase transition is also observed in the 2H-NMR spectra, not so much by a change in 
the quadrupole splitting but by a distinct line broadening.  
 
The most unusual properties are observed for DMPG-Na+ samples at low lipid 
content and low salt concentrations. The DSC diagram displays a broad transition 
region between 17 to 35 °C with several peaks, the intensity of which changes with 
consecutive scans (fig. 4B).34 The transition enthalpy remains, however, constant at 
6.1 ± 0.2 kcal/mol.  
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Figure 5: 31P- and 2H-NMR anisotropy parameters at low lipid molalities (lipid molality ≤ 50 
mmol/kg) 
The lipid molality was typically 30 mmol/kg. (●) 100 mM NaCl, 10 mM Hepes, pH 7.4. (○) 2 mM 
NaCl, 10 mM Hepes, pH 7.4. (♦) repeats the data of figure 1 obtained at high lipid 
concentration and 100 mM NaCl. (A) 31P-NMR. Phosphorus chemical shielding anisotropy Δσ. 
(B) 2H-NMR. Quadrupole splitting of the terminal CD3 groups. (C) 
2H-NMR. ΔνQ of the largest 
splitting of the CD2-groups.  
 
The corresponding 31P- and 2H-NMR spectra (50 mmol/kg DMPG-Na+, 2 mM 
NaCl, 10 mM Hepes, pH 7.4) are displayed in figures 6 and 7, respectively. Above the 
phase transition, at 30 and 35 °C, both 31P- and 2H-NMR show bilayer spectra of lipid 
membranes in the liquid-crystalline state. The 31P-NMR spectrum at 35 °C also contains 
an isotropic component which increases in intensity as the temperature is raised even 
further.  
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Figure 6: 31P-NMR spectra of non-deuterated DMPG at low lipid content in low ionic strength 
buffer at different temperatures 
13.7 mg of DMPG was dispersed in 400 µL of low ionic strength buffer (2 mM NaCl, 2 mM 
Hepes, pH 7.4) (lipid molality  46.2 mmol/kg). The red lines are the spectral simulations. The 35 
°C spectrum contains a small contribution from an isotropic line. 
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Figure 7: 2H NMR spectra of deuterated DMPG at low lipid content in low ionic strength at 
different temperatures 
10.3 mg of DMPG and 3.5 mg of d54-DMPG was dispersed in 400 µL of low ionic strength buffer 
(2 mM NaCl, 10 mM Hepes, pH 7.4) (lipid molality 46.5 mmol/kg). The red line represents the 
spectral simulation assuming a distribution of quadrupole splitting. The inserts represents the 
normalized order profiles used for the simulation.  
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Unusual 31P- and 2H-NMR spectra are however obtained between 20 and 25 °C. 
Such spectra have hitherto not been observed for bilayer systems. In particular, the 
31P-NMR spectrum at 25 °C consists of a narrow resonance, similar to that predicted 
for an isotropic phase. This is however contradicted by the 2H-NMR spectrum at the 
same temperature which documents an anisotropic motion of the hydrocarbon chains 
(fig. 7). The narrow 31P-NMR resonance is thus caused by a specific orientation of the 
phosphoglycerol headgroup with respect to the bilayer normal. If the temperature is 
further lowered to 21 °C, the 31P-NMR spectrum becomes similar in shape to the 35 °C 
spectrum albeit with a Δσ of only -20 ppm. The temperature dependence of Δσ is 
shown in figure 5A (○). The dip in Δσ is even more pronounced than reported in figure 
2A () for high lipid, but low salt concentration.  
The unusual behavior of the DMPG-Na+ headgroup is also reflected in the 2H-
NMR spectra of the deuterated hydrocarbon chains. At 35 °C and 30 °C (fig. 7) the 
spectra correspond to normal bilayers with the classical order profile and well-resolved 
resonances. In contrast, at 25 °C and 20.6 °C, the spectra show no individual 
resonances (except for the terminal CD3-groups). They are characterized by a 
completely different order profile which is caused by a continuous distribution of 
gradually decreasing quadrupole splittings. Figure 5 summarizes the quadrupole 
splittings of the methyl groups (5B, ○) and the maximum splitting of the –CD2-
segments (5C, ○). The size and the temperature dependence of these splittings are not 
much different from those obtained at high salt concentration (●). The main difference 
is thus the shape of the order profiles.  
After measuring at high temperatures the NMR-samples were taken out of the 
probe-head and turned upside-down several times. By this procedure the samples 
became completely transparent both at low and high ionic strength. The 31P-NMR of 
these samples showed an isotropic line with Lorentzian lineshape and full-width-at-
half height (FWHH) 850 Hz. The corresponding 2H-NMR spectrum was also isotropic 
but composed of 2 lorentzians of FWHH = 280 Hz and 3000 Hz. As there are 24 
deuterons in CD2 segments and 3 in the CD3 terminal we assign the sharp resonance to 
the CD3 groups, the broader one to the CD2 groups. 
When the sample was stored for several months at 4 °C, a bilayer spectrum was 
partially recovered.  
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5. Discussion 
The most characteristic property of phospholipids, which distinguishes this 
class of molecules from all other biomolecules, is their polymorphic behavior. 
Depending on the physiological conditions such as temperature, ion concentration, pH 
etc. structurally different mesophases can be formed. Gel-to-liquid-crystal phase 
transitions of the most abundant natural lipids usually occur below 0 °C and have not 
been investigated extensively. In contrast, phase transitions of synthetic lipids with 2 
saturated chains are characterized by distinctly higher transition temperatures. Among 
these, the anionic 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol has attracted 
particular attention as its phase diagram exhibits rather unusual features and is clearly 
more complex than that of its zwitterionic analog 1,2-dimyristoyl-sn-glycero-3-
phosphocholine. In the present study we use NMR methods to deduce both the long-
range organization and the dynamic molecular conformation of DMPG-Na+ under a 
variety of conditions. Not all phase transitions detected with DSC and other methods 
are accessible to NMR. NMR is well suited for liquid-crystalline material but in solids 
the NMR lines become too broad to provide useful information in the present context.  
 
Order profiles of the hydrocarbon chains. The quadrupole splittings, ΔνQ, 
derived from the 2H-NMR spectra describe the average conformation and fluctuations 
of the flexible hydrocarbon chains. An unambiguous assignment of the resonances is 
only possible with selectively labeled lipids 33. For the perdeuterated hydrocarbon 
chains studied here we assume a sequential decrease in the size of the quadrupole 
splitting starting from the headgroup region with the largest splitting towards the 
bilayer interior with the smallest ΔνQ. The quadrupole splitting, ΔνQ, can be translated 
into a molecular order parameter, SCD, according to  
2
Q CD
3 e qQ
S
4 h
n    
 
where (e2qQ/h) = 167 kHz is the quadrupole coupling constant and ΔνQ is the most 
intense splitting in powder-type spectra. A maximum quadrupole splitting of 26.2 kHz, 
as observed at 30 °C for the 2H-NMR spectrum in figure 7, corresponds to SCD = - 0.21. 
The negative sign follows from measurements of related systems.29 The inserts in 
figure 7 show the relative order profiles necessary to simulate the experimental 2H-
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NMR spectra. To facilitate the comparison the order profiles are normalized such that 
S = 1 is assigned to the largest splitting in the spectrum. In the liquid-crystalline state 
(spectra at 30 °C and 35 °C), the order profiles show constant order parameters for the 
first 10 chain segments, but decrease rapidly for the last 4 segments as the tail of the 
hydrocarbon chain gains more motional freedom in the bilayer interior. This type of 
order profile has been observed for many other bilayers. However, unusual and not 
observed so far in bilayer structures are the order profiles of DMPG-Na+ in the region 
of the phase transition (spectra at 25 °C and 21 °C). The 31P-NMR spectra (figure 6) 
provide evidence that the headgroups are still in a highly fluid environment. 
Nevertheless, it is not possible with 2H-NMR to resolve individual quadrupole splitting 
of the hydrocarbon chains as the order profile decreases more rapidly than observed 
at higher temperatures (e.g. 30 °C). The envelope of the quadrupole splittings can be 
simulated by the order profile shown as inserts. Each segment adds approximately the 
same incremental contribution to chain flexing which leads to a more rapid decrease in 
S. The plateau region observed at 30 °C and 35 °C is replaced by a continuous decrease 
of the order parameter at 25 °C and 21 °C. 
Knowledge of the order profile allows a determination of the average or 
projected length, <L>, of the fatty acyl chain according to  
L(n) Å = 1.25
n
(i)
CD
i
n
S
2 
 
 
 
  
 
where n is the number of chain segments.33,35 For a rigid all-trans chain, rotating 
rapidly around its long axis (i)CDS  = -0.5 for all segments. The maximum length of a 
myristic acid chains (12C-C segments, neglecting the CO-CH2 segment) is thus 15 Å. In 
contrast, in the liquid-crystalline state the average (or projected) chain length is 
distinctly reduced due to the flexing motions produced by trans-gauche rotations 
around the carbon-carbon single bonds. Based on the order profiles shown in figure 7 
we determine a chain length of L(12) = 11.2 Å at 30 °C for the liquid-crystalline bilayer 
region and L(12) = 10.8 Å at 25 °C in the transition region. The latter result is quite 
surprising as a phase transition to lower temperature usually produces chain stiffening. 
For DMPG-Na+ at low salt concentration the opposite is observed. Immediately below 
the main transition the hydrocarbon chains adopt an even more coiled conformation. 
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Shorter hydrocarbon chains require a larger chain cross section as the volume remains 
constant. The increase in chain-chain spacing has distinct consequences for the 
orientation of the phosphoglycerol headgroup.  
 
Molecular structure of DMPG headgroup in the bilayer phase. The analysis of 
the 31P- NMR spectra provides quantitative insight into the orientation of the 
phosphoglycerol headgroup. The quantitative analysis leads to the molecular structure 
shown in figure 8 for DMPG at low lipid concentration and low ionic strength. Using 
the crystal structures obtained for 1,2-dimyristoyl-sn-glycero-3-phosphocholine 36, 
DMPG 37, and glycerylphosphocholine 38 it is possible to explain the NMR data in terms 
of a dynamic model 39, in which the glycerol headgroup fluctuates rapidly between two 
mirror-like conformations. The torsion and bond angles of the headgroup segments 
used in figure 8 are identical to those given in reference.39 The change in the 
headgroup orientation and, in turn, Δσ is brought about exclusively by the C2-C3-O-P 
torsion angle, i.e. the rotation around the C3-O bond (C2-C3 ≙ carbon atoms of the 
glycerol backbone) (cf. atom labeling in figure 8). Figure 8 describes the two extreme 
situations observed in this study. Figure 8A corresponds to the 30 °C spectrum in figure 
6 with Δσ = -34 ppm; figure 8B displays the headgroup orientation at 25 °C with Δσ = -
4 ppm. The arrow represents the orientation of a virtual dipole between the P-atom 
and the terminal OH group at 30 °C. Its orientation is left unchanged in 8B to better 
illustrate the movement of the glycerol headgroup. At 30 °C the phosphoglycerol 
dipole makes an angle αdipole ~ 12° with the bilayer surface. As the temperature is 
reduced to 25 °C, the headgroup moves closer to the hydrocarbon layer such that the 
oxygen-end points into the hydrocarbon interior with αdipole = -16°. As the temperature 
is further lowered to 21 °C, the headgroup moves back towards the water phase and 
its dipole is almost exactly parallel to the bilayer surface with αdipole = 2°.  
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Figure 8: Orientation of the phosphoglycerol headgroup 
The figure shows the change in orientation of the phosphoglycerol headgroup as the 
temperature changes from 30 °C (A) with Δσ = -34 ppm to 25 °C (B) with Δσ = -4 ppm. The 
torsion angles are those listed in reference 39 for the NMR experiment with 
glycerylphosphocholine. The variation in Δσ can be explained by a ~30 ° rotation around the 
C(3)-O1 axis of the C(2)-C(3)-O1-P segment, which connects the headgroup with the glycerol 
backbone. For convenience the hydrocarbon chains are left in the rigid all-trans-conformation, 
even though the order profiles of figure 7 provide evidence for extensive segmental fluctuations 
perpendicular to the bilayer normal. The blue arrow in (A) connects the P-atom with the 
terminal glycerol-oxygen atom and is only introduced to guide the eye. Its orientation is not 
changed in (B) to better indicate the movement of the glycerol headgroup.  
 
The unusual movement of the PG headgroup is caused exclusively by a change 
of the C2-C3-O-P torsion angle and is correlated with a change in the membrane surface 
charge. For the zwitterionic phosphatidylcholine it is known that the polar headgroup 
is sensitive to the surface charge (molecular voltmeter concept).40,41 In neutral POPC 
bilayers the P-N dipole makes an angle of 23° with the bilayer surface and               
Δσ ≈ -50 ppm. The addition of cationic molecules to the bilayer surface moves the N-
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tip of the dipole into the aqueous phase, the insertion of anionic molecules induces the 
opposite rotation. It appears that the same physical principle can be invoked to explain 
the movement of the glycerol headgroup of DMPG-Na+. Conductivity measurements 
have shown that the electrical conductivity of DMPG-Na+ dispersions at low ionic 
strength goes through a pronounced maximum in the temperature interval of 15-
40 °C.34,42 Model calculations reveal that the degree of Na+ dissociation of DMPG-Na+ 
bilayers changes from αion = 0.27 at 21 °C (Δσ = -20 ppm), to αion = 0.33 at 25 °C         
(Δσ = -4ppm) to αion = 0.16 (Δσ = -34 ppm) at 30 °C. Including the result for neutral 
POPC as αion = 0 (Δσ = -50 ppm) we obtain an approximately linear relationship 
between Δσ (and, in turn, αdipole) and the membrane surface charge. The direction of 
the change is the same as observed for phosphatidylcholine. The larger the negative 
surface charge, the closer the glycerol headgroup to the hydrocarbon layer. As the 
choline residue has a positively charged  
33
CHN

  endgroup while the glycerol 
residue is neutral with an OH terminal, the identical reaction of both residues to 
negative charge suggests that the main interaction occurs close to the phosphate 
group. Molecular dynamics calculations are performed at present to provide a more 
detailed insight.  
 
 Phase properties of DMPG bilayers. A large series of experiments has led to the 
conclusion that DMPG dispersions at low lipid and low salt concentrations give rise to 
fragmented structures or tattered bilayer sheets.19,23,34 This would produce an almost 
isotropic motion of lipid molecules in the rim region and give rise to isotropic NMR 
spectra. However, deuterium-and phosphorus-NMR spectra with bilayer 
characteristics were observed even under these conditions. The temperature interval 
between 20 and 30°C showed bilayer-like long-range order but with short-range order 
different from classical bilayers. The order profile indicated a more disordered 
hydrocarbon region and the lipid headgroups were found to move closer to the bilayer 
interior. Above 30°C the NMR spectra had the typical fluid-like bilayer signature with 
disordered hydrocarbon chains, below 20° the characteristics of extended hydrocarbon 
chains in the gel-state were observed. At a high lipid concentration but low-salt, the 
deuterium NMR spectra revealed the coexistence of two lipid bilayers, in agreement 
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with earlier EPR studies.43 These data could always be reproduced if freshly prepared 
lipid samples were used for the experiments. Unusual phase properties were however 
observed upon prolonged heating of the NMR samples to 55°C. This generated NMR 
signals characteristic of an isotropic motion of lipids. The bilayer signal could only be 
recuperated if the samples were stored for several months at 4°C and then warmed up 
again. In agreement with earlier reports 24 this suggests that temperatures below 10 
and above 50°C can produce metastable states which may not easily return to 
thermodynamic equilibrium situations.  
In conclusion, the NMR data have shown that DMPG-Na+ aqueous dispersions 
display bilayer-like structures under all conditions measured. Micellar structures were 
not observed. At low salt concentrations and at temperatures between 20 to 25 °C the 
phosphocholine headgroup rotates closer to the hydrophobic part. The extent of 
rotation can be linearly correlated with the negative membrane surface charge, that is, 
the extent of ionization of DMPG-Na+. 
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XI. Appendix: Thermal phase behavior of DMPG 
 
 
 
Lipid bilayers generally adopt two packing geometries depending on the 
temperature. At temperatures below the melting temperature, Tm, they are in the 
highly ordered gel phase. At temperatures higher than Tm, the lipids are in the liquid 
crystalline phase. DMPG, in contrast to most other phospholipids, does not have a 
single melting temperature, but shows a more elaborate phase diagram at low ionic 
strength. The structure adopted by DMPG in this temperature range is unusual and 
was studied in the previous manuscript (Chapter X). 
 
 
1. DMPG at high lipid content 
A particularly prominent feature of DMPG is its change in optical appearance at 
high lipid content with the temperature. This is true for DMPG both at high and low 
ionic strength. Figure 1 shows the sample of DMPG at high lipid content and low ionic 
strength. At 10°C, DMPG looks milky and opaque. At room temperature, the formation 
of white cloud-like structures is observed in the lipid dispersion. At 50°C the mixture 
becomes completely transparent and jelly-like.  
The change in optical appearance is not the only unusual feature of DMPG. 
After the upwards temperature scan, if the NMR sample at high lipid content is gently 
shaken, it becomes transparent and fluid: it shows very low viscosity under gentle 
agitation. This applies for the samples at high lipid content, both in low or high ionic 
strength, if they are kept a few hours at high temperature (~ 50°C) and then gently 
shaken.  
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Figure 1: DMPG at high lipid content (290 mM) dispersed in low ionic strength buffer (10mM 
HEPEs, 2mM NaCl, pH7.4). The temperature of the sample is (A) 10, (B) 25 and (C) 50°C, 
respectively.  
 
This particular effect was further investigated. The 2H-NMR spectra of a sample 
at high lipid content and low ionic strength is shown in Figure 2. The freshly prepared 
sample was measured at high temperature (40-55°C) with 2H-NMR and the recorded 
spectra are shown at the bottom of Figure 2. At the end of these measurements, the 
sample was transparent and fluid. The sample was still transparent after two weeks of 
storage at 8°C. This transparent sample was measured with 2H-NMR and led to 
isotropic peaks. They are shown at the top of Figure 2.  
 
Figure 2: 2H-NMR spectra of DMPG at high lipid concentration and low ionic strength at 
different temperatures. 290 mM DMPG/d54-DMPG (3:1, mol/mol) was dispersed in low ionic 
strength buffer (2 mM NaCl, 10 mM HEPEs, pH 7.4). 
Temperature from bottom to top: 40, 45, 50 and 55°C, the sample was measured again after 2 
weeks at 15, 18, and 19°C. 
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The isotropic phase was studied further with a freshly-prepared sample at high 
lipid content and high ionic strength. The sample was first measured in the gel and in 
the liquid-crystal phase with 2H-NMR (Figure 3A).  
 
 
Figure 3: (A, B) 2H- and (C) 31P-NMR spectra of DMPG at high lipid concentration and high ionic 
strength at different temperatures. 290 mM DMPG/d54-DMPG (3:1, mol/mol) was dispersed in 
high ionic strength buffer (100 mM NaCl, 10 mM HEPEs, pH 7.4). 
Temperature from bottom to top: (A) 15, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 54°C, 
(B) 20, 25, 30, and 35°C, (C) 22, 40, 55, and 25°C. 
 
At the end of the experiments at high temperature (Figure 3A), the sample was 
transparent and fluid, as described at high lipid content and low ionic strength. The 
isotropic phase was studied with 2H-NMR after two weeks (Figure 3B), and with 31P-
NMR after three weeks of storage at 8°C (Figure 3C). The sharp line observed in 2H-
NMR is paralleled by a broader peak in 31P-NMR at low temperature. Upon 
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temperature increase the broad peak also converts into a sharp isotropic line in 31P-
NMR.  
 
 
2. DMPG at low lipid content 
At low lipid content, the samples have a different optical appearance in 
contrast to the sample at high lipid content. DMPG at low lipid content in high ionic 
strength looks turbid at room temperature and becomes transparent at high 
temperatures, similarly to the samples at high lipid content. In contrast, DMPG at low 
lipid content and low ionic strength is transparent at all temperatures. Figure 4 shows 
the samples at low lipid content and high or low ionic strength at room temperature. 
 
Figure 4: DMPG at low lipid content (50 mM) in (left) high and (right) low ionic strength at 
room temperature.  
 
A solid-state NMR study at low lipid content was performed at high and low 
ionic strength. Figure 5 shows the recorded 31P and 2H spectra. For this study, four 
distinct samples were freshly prepared. The spectra of the sample at high ionic 
strength (see Figure 5A and C) are typical for a lipid bilayer. The spectra at low ionic 
strength (see Figure 5B and D) have unusual characteristics and are discussed in the 
manuscript (Chapter X).  
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Figure 5: 31P- (A, B) and 2H-NMR (C, D) spectra of DMPG at low lipid concentration and at 
different temperatures. 50 mM (A) DMPG or (C) DMPG/d54-DMPG (3:1, mol/mol) was dispersed 
in high ionic strength buffer (100 mM NaCl, 10 mM HEPEs, pH 7.4). 50 mM (B) DMPG or (D) 
DMPG/d54-DMPG (3:1, mol/mol) was dispersed in low ionic strength buffer (2 mM NaCl, 10 mM 
HEPEs, pH 7.4). 
Temperature from bottom to top: (A) 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 45, 50, 55°C, (B) 17, 
19, 21, 25, 30, 35, 40, 45, 50, 55, sample taken out of the probe head and measured at 20, and 
31°C, (C) 20, 22, 24, 26°C, sample heated up to 55°C, taken out of the probe head and 
measured at 20°C, (D) 21, 25, 30, 35, 40, 45, 50, 55°C, sample taken out of the probe head and 
measured at 20°C after 2 weeks. 
 
The interesting feature observed in the NMR spectra (Figure 5) is that the 
samples at low lipid content and low or high ionic strength show thixotropy, similarly 
to the samples at high lipid content. If they are gently shaken after the experiments at 
high temperature and measured again, the spectra show an isotropic line (see the two 
upper spectra in Figure 5B, the top spectrum in Figure 5C, and the top spectrum in 
Figure 5D).  
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It was observed that the isotropic phase could be reached by prolonged heating 
of the sample after the freeze-thaw procedure. For this purpose the sample was 
heated above the melting transition, at 50°C, and vortexed. Successive cycles of 
heating at 50°C and vortexing were repeated until the sample becomes transparent.  
The stability of the isotropic phase was investigated over time in a sample at 
low lipid content and low ionic strength. This sample did not contain deuterated lipid 
in order to eliminate the possibility of a particular interaction due to the deuterons on 
both acyl chains of DMPG. It was successively heated at 50°C and vortexed in order to 
reach directly the isotropic phase, as described in the previous paragraph. The 31P-
NMR spectra of the non-deuterated sample are show in Figure 6.  
The isotropic phase is observed also in the non-deuterated sample at low lipid 
content and low ionic strength. The intensity of the isotropic line increases with the 
temperature and a slight shift in the frequencies is observed, from 1 to 3 ppm (see 
Figure 6A). After one month of storage at 8°C, a broader peak is superimposed on the 
isotropic line (see Figure 6B). Furthermore the several phases observed in the DMPG 
system have properties that change over time, even 11 months after the dispersion of 
DMPG in buffer (see Figure 6C). 
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Figure 6: 31P-NMR spectra of DMPG at low lipid concentration and low ionic strength at 
different temperatures and after different storage periods. 50 mM DMPG was dispersed in low 
ionic strength buffer (2 mM NaCl, 10 mM HEPEs, pH 7.4).The sample was successively heated 
at about 50°C and vortexed. This heat-vortex cycle was repeated until the sample was 
transparent.  
(A) Fresh sample measured from bottom to top at 23, 23, 13, and 33°C. (B) The sample was 
measured at 23°C immediately, and at 25°C after 30 and 37 days, from bottom to top. (C) 
Sample stored 11 months at 8°C and then measured at 0, 5, 10, 15, and 20°C, from bottom to 
top. 
 
Repeating this experiment with a freshly-prepared non-deuterated sample 
leads to similar but not identical results. Figure 7A shows the 31P-NMR spectra of a 
second sample at low lipid content and low ionic strength. This sample was prepared in 
order to reach directly the isotropic phase, as described above. After a few months at 
8°C, the sample is not completely transparent anymore but it contains a few white 
clouds that disappear under vortexing. The 31P-NMR spectra of this aged sample are 
shown in Figure 7B. The phase properties of the DMPG system changed within 3 
months. 
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 Figure 7: 31P-NMR spectra of DMPG at low lipid concentration and low ionic strength at 
different temperatures. 50 mM DMPG was dispersed in low ionic strength buffer (2 mM NaCl, 
10 mM HEPEs, pH 7.4). The sample was successively heated at about 50°C and vortexed. This 
heat-vortex cycle was repeated until the sample was transparent.  
(A) Condition from bottom to top:  the sample was measured at 25°C, after 45 days it was 
measured at -15, 5 and 2°C. (B) after 3 months, temperature from bottom to top: 15, 20, 25, 
30, 35, 40 and 50°C.    
 
Another unusual feature of DMPG at low lipid content and low ionic strength is 
the continuous shift of the phase transition observed in the calorimetric profile 
(Chapter X, Figure 4D). This shift could be due to degradation of the sample due to 
hydrolysis, for example, as mentioned in the manuscript. Therefore the integrity of the 
sample was checked by mass spectrometry (MALDI-TOF) by comparing a freshly 
prepared sample with a sample used in a series of DSC scans. The results are shown in 
Figure 8.  
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Figure 8: Mass spectra of (A) freshly prepared DMPG or (B) DMPG at the end of the DSC scans. 
The mass at 666 g.mol-1 represents DMPG without the sodium cation and the one at 447 g.mol-
1 represents the matrix (sinapinic acid).  
 
The two mass spectra are similar and do not show a major product other than 
DMPG or the matrix. The lipid sample is not decomposed and the shift observed in the 
calorimetric profile is only due to variations in the lipid phase transition. 
 
Additional solid-state NMR spectra and their description are presented 
thereafter (Figure 9-14).  
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Figure 9: 2H-NMR spectra of DMPG at high lipid content and high ionic strength. 290 mM 
DMPG/d54-DMPG (3:1, mol/mol) was dispersed in high ionic strength buffer (100 mM NaCl, 10 
mM HEPEs, pH 7.4). The 2H-NMR spectra of the fresh sample are shown in Figure 3A. At the end 
of the measurements at high temperature, the sample was transparent and fluid. Figure 9 
shows the spectra of the same sample recorded 6 weeks later. 
Temperature from bottom to top: 25 and 45°C.  
 
 
 
 
 
 
Figure 10: 31P-NMR spectra of DMPG at low lipid content and low ionic strength. 50 mM 
DMPG/d54-DMPG (3:1, mol/mol) was dispersed in low ionic strength buffer (2 mM NaCl, 10 mM 
HEPEs, pH 7.4).  
Temperature from bottom to top: 21, 30, 40, 55°C.  
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Figure 11: 2H-NMR spectra of DMPG at low lipid content and low ionic strength. 50 mM 
DMPG/d54-DMPG (3:1, mol/mol) was dispersed in low ionic strength buffer (2 mM NaCl, 10 mM 
HEPEs, pH 7.4). The 2H-NMR spectra of the fresh sample are shown in Figure 5D. At the end of 
the measurements at high temperature, the sample was transparent and fluid. Figure 11 shows 
the spectra measured from this transparent and fluid sample.  
Temperature from bottom to top: 10, 20, 30 and 40°C.  
 
If the sample is kept at high temperature in the probe head, the isotropic phase 
can be reached as well but the line is less sharp. Figure 12-14 show examples at high 
lipid content and low ionic strength (Figure 12 and 13), and at low lipid content and 
high ionic strength (Figure 14).  
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Figure 12: 2H-NMR spectra of DMPG at high lipid content and low ionic strength. 290 mM 
DMPG/d54-DMPG (3:1, mol/mol) was dispersed in low ionic strength buffer (2 mM NaCl, 10 mM 
HEPEs, pH 7.4).  
Temperature from bottom to top: 20, 25, 30, 50, 55, 25, 56, sample let at 55°C and measured 
after 12 h at 25°C. The sample remains in the probe head during this whole series of 
measurements. 
 
 
 
  
 
Figure 13: 2H-NMR spectra of DMPG at high lipid content and low ionic strength. 290 mM 
DMPG/d54-DMPG (3:1, mol/mol) was dispersed in low ionic strength buffer (2 mM NaCl, 10 mM 
HEPEs, pH 7.4).  
Temperature from bottom to top: 60, 60, 60, 60, 60, 25, 25 and 25°C. The sample remains in 
the probe head during this whole series of measurements. 
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Figure 14: 2H-NMR spectra of DMPG at low lipid content and high ionic strength. 50 mM 
DMPG/d54-DMPG (3:1, mol/mol) was dispersed in high ionic strength buffer (100 mM NaCl, 10 
mM HEPEs, pH 7.4).  
Temperature from bottom to top: 21, 25, 30, 35, 40, 45, 50, 55, 19, 17, and 25°C.The sample 
remains in the probe head during this whole series of measurements. 
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XII. Summary 
 
 
  
The aim of this work was to characterize the structural modifications of model 
β-amyloid peptides and the lipid membrane upon binding. The first step of this thesis 
was to reproduce the random-coil to β-sheet structural transition of βAP(25-35). It 
appeared that additional energy, brought by stirring or heating, acts as a catalyst of 
the structural transition. Also the presence of inhomogeneous aggregates of βAP(25-
35) in the solution influences the CD spectra and thereby the analysis of the peptide 
secondary structure. This work points out the experimental factors that can strongly 
influence βAP(25-35) secondary structure and make biophysical studies difficult. In this 
study, an α-helical intermediate was observed for the first time in the random-coil to 
β-sheet transition of βAP(25-35).  
βAP(25-35) has no chromophore and the quantification of the peptide content 
was difficult, in particular under conditions of aggregation. Amyloid model peptides 
were therefore synthesized. The insertion of Trp either at position 24 or 32 of βAP(25-
35) resulted in two analog peptides, WβAP(25-35) and βAP(25-35)_I32W. They form 
aggregates in aqueous buffers at micromolar peptide concentrations, similar to 
βAP(25-35). HFIP pretreatment homogenizes WβAP(25-35) solutions at physiological 
and acidic pH values. The aggregates of βAP(25-35)_I32W are small and no effect of 
HFIP pretreatment was observed. Aggregates with sizes ranging from 60 to 600 nm are 
measured with dynamic light scattering for the three pretreated peptides. 
Nevertheless fibril formation of the two analogs could not be observed with Thioflavin 
T fluorescence, in contrast to βAP(25-35). The presence of Trp in WβAP(25-35) and 
βAP(25-35)_I32W seems to hinder the binding of the fluorescent dye. Our work opens 
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new possibilities in the design of amyloid model peptides that can facilitate structural 
and thermodynamic studies.  
CD spectroscopy showed that the presence and position of Trp influences the 
secondary structure of the free and the lipid-bound amyloid model peptides. The lipid 
membrane favors the random-coil structure of βAP(25-35) and WβAP(25-35) at low 
peptide concentration. This shows the dual role of the membrane which can enhance 
β-sheet content in the peptide structure at higher peptide concentrations. 
Thermodynamic parameters of the peptide-to-lipid binding could be determined at pH 
4.0. In addition, we demonstrated with solid-state NMR that the insertion of the 
amyloid model peptides into the lipid membrane influences the fluidity of the lipid acyl 
chains. In contrast, the association of aggregated amyloid model peptides from the 
aqueous phase with the lipid membrane leads to the formation of an isotropic phase. 
This phenomenon is reported here for the first time and might be correlated with the 
toxicity of the amyloid peptide on the neuronal cells. 
The NMR study of DMPG at high lipid content proved that DMPG is in a bilayer 
state at low and high salt content. At high ionic strength, the phase transition occurs at      
24°C.  At low ionic strength, two distinct bilayer phases are observed on the NMR 
spectra; they are characterized by a broad phase transition between 20 and 24°C. The 
results obtained at low lipid content and high ionic strength are similar to those at high 
lipid content: bilayer features are observed on the whole temperature range and the 
gel-to-liquid-crystal transition occurs at 23°C, as proved with DSC and NMR data. At 
low lipid content and low ionic strength, bilayer characteristics are also observed on 
the whole temperature range in the 2H-NMR spectra. In contrast, during the phase 
transition, an isotropic line is observed in the 31P-NMR spectra. Spectral fitting 
indicated that at low ionic strength, the phase transition is characterized by enhanced 
motions of the acyl chains and a change in the orientation of the phosphoglycerol 
headgroup. In addition, we observed thixotropy in all samples upon prolonged heating, 
independently of the lipid or salt content.  
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